An analysis of the attrition of drug candidates from fou

Citation Report

#	ARTICLE	IF	CITATIONS
1	The expanding utility of microdosing. Clinical Pharmacology in Drug Development, 2015, 4, 401-406.	0.8	14
2	Unknown unknowns in biomedical research: does an inability to deal with ambiguity contribute to issues of irreproducibility?. Biochemical Pharmacology, 2015, 97, 133-136.	2.0	35
3	1. Overview of chemical drug design. , 2016, , 1-14.		0
4	Is Super-Selective Superior?. Journal of Crohn's and Colitis, 2016, 10, 1129-1131.	0.6	0
5	Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. ALTEX: Alternatives To Animal Experimentation, 2016, 33, 272-321.	0.9	214
6	Towards Creating the Perfect *In Vitro* Cell Model. Stem Cells International, 2016, 2016, 1-2.	1.2	7
7	Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Brazilian Journal of Medical and Biological Research, 2016, 49, e5646.	0.7	99
8	How Reliable Are Ligand-Centric Methods for Target Fishing?. Frontiers in Chemistry, 2016, 4, 15.	1.8	21
9	An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates. Frontiers in Immunology, 2016, 7, 462.	2.2	3
10	The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. International Journal of Molecular Sciences, 2016, 17, 1714.	1.8	73
11	Opportunities to Apply the 3Rs in Safety Assessment Programs. ILAR Journal, 2016, 57, 234-245.	1.8	18
12	Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development. Oncotarget, 2016, 7, 44790-44802.	0.8	51
13	hERG quality control and the long QT syndrome. Journal of Physiology, 2016, 594, 2469-2481.	1.3	37
14	Poly(lactic acid) blends in biomedical applications. Advanced Drug Delivery Reviews, 2016, 107, 47-59.	6.6	377
15	Probing Protein Surfaces: QSAR Analysis with Helix Mimetics. ChemBioChem, 2016, 17, 768-773.	1.3	5
16	Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3429-3435.	1.0	41
17	The nematode Caenorhabditis elegans as a tool to predict chemical activity on mammalian development and identify mechanisms influencing toxicological outcome. Scientific Reports, 2016, 6, 22965.	1.6	53
18	The Discovery and Synthesis of the CGRP Receptor Antagonist MK-3207. ACS Symposium Series, 2016, , 63-136.	0.5	4

#	ARTICLE	IF	CITATIONS
19	The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development. ILAR Journal, 2016, 57, 186-211.	1.8	35
20	Data Standardization, Pharmaceutical Drug Development, and the 3Rs. ILAR Journal, 2016, 57, 109-119.	1.8	8
21	Computational phenotypic assessment of small molecules in drug discovery. , 0, , 94-113.		0
22	The impact of early human data on clinical development: there is time to win. Drug Discovery Today, 2016, 21, 873-879.	3.2	11
23	A complex game of hide and seek: the search for new antifungals. MedChemComm, 2016, 7, 1285-1306.	3.5	50
24	Discovery of a novel oxime ether scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists. RSC Advances, 2016, 6, 46356-46365.	1.7	22
25	Stacking with No Planarity?. ACS Medicinal Chemistry Letters, 2016, 7, 341-344.	1.3	24
26	Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy. Trends in Molecular Medicine, 2016, 22, 430-445.	3.5	187
27	Liquid-based three-dimensional tumor models for cancer research and drug discovery. Experimental Biology and Medicine, 2016, 241, 939-954.	1.1	82
28	The emerging role of in vitro electrophysiological methods in CNS safety pharmacology. Journal of Pharmacological and Toxicological Methods, 2016, 81, 47-59.	0.3	43
29	The common marmoset as an indispensable animal model for immunotherapy development in multiple sclerosis. Drug Discovery Today, 2016, 21, 1200-1205.	3.2	22
30	Modelling and shadowgraph imaging of cocrystal dissolution and assessment of in vitro antimicrobial activity for sulfadimidine/4-aminosalicylic acid cocrystals. European Journal of Pharmaceutical Sciences, 2016, 89, 125-136.	1.9	41
31	BDDCS, the Rule of 5 and drugability. Advanced Drug Delivery Reviews, 2016, 101, 89-98.	6.6	475
32	Setting Global Standards for Stem Cell Research and Clinical Translation: TheÂ2016 ISSCR Guidelines. Stem Cell Reports, 2016, 6, 787-797.	2.3	172
33	Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System. Drug Metabolism and Disposition, 2016, 44, 1731-1735.	1.7	42
34	Multiparametric Analysis of Oncology Drug Screening with Aqueous Two-Phase Tumor Spheroids. Molecular Pharmaceutics, 2016, 13, 3724-3735.	2.3	39
35	The promises of quantitative systems pharmacology modelling for drugÂdevelopment. Computational and Structural Biotechnology Journal, 2016, 14, 363-370.	1.9	77
36	Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Internal Medicine, 2016, 176, 1826.	2.6	279

#	Article	IF	Citations
37	Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist. ACS Medicinal Chemistry Letters, 2016, 7, 1134-1138.	1.3	8
38	The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system. Expert Opinion on Drug Discovery, 2016, 11, 939-956.	2.5	10
39	2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. Journal of Medicinal Chemistry, 2016, 59, 7311-7351.	2.9	35
40	Concise SAR Exploration Based on the â€œHead-to-Tailâ€•Approach: Discovery of PI4KIIIÎ± Inhibitors Bearing Diverse Scaffolds. ACS Medicinal Chemistry Letters, 2016, 7, 919-923.	1.3	7
41	A BOILEDâ€Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem, 2016, 11, 1117-1121.	1.6	1,249
42	Melting Point Distribution Analysis of Globally Approved and Discontinued Drugs: A Research for Improving the Chance of Success of Drug Design and Discovery. ChemistryOpen, 2016, 5, 357-368.	0.9	17
43	Assessment of Free Drug Concentration in Cyclodextrin Formulations Is Essential to Determine Drug Potency in Functional InÂVitro Assays. Journal of Pharmaceutical Sciences, 2016, 105, 2913-2920.	1.6	3
45	Computational approaches for the study of the role of small molecules in diseases. Perspectives in Science, 2016, 9, 49-52.	0.6	3
46	Understanding Cytotoxicity and Cytostaticity in a High-Throughput Screening Collection. ACS Chemical Biology, 2016, 11, 3007-3023.	1.6	35
47	Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Scientific Reports, 2016, 6, 29930.	1.6	29
48	Quality guidelines for oral drug candidates: dose, solubility and lipophilicity. Drug Discovery Today, 2016, 21, 1719-1727.	3.2	83
49	Access to Cyclopropyl-Fused Azacycles via a Palladium-Catalyzed Direct Alkenylation Strategy. Organic Letters, 2016, 18, 6046-6049.	2.4	36
50	Disciplined approach to drug discovery and early development. Science Translational Medicine, 2016, 8, 349ps15.	5.8	79
51	Compilation and physicochemical classification analysis of a diverse hERG inhibition database. Journal of Computer-Aided Molecular Design, 2016, 30, 1175-1188.	1.3	22
52	Dichotomy of cellular inhibition by small-molecule inhibitors revealed by single-cell analysis. Nature Communications, 2016, 7, 12428.	5.8	20
53	High-resolution laser ablation-inductively coupled plasma-mass spectrometry imaging of cisplatin-induced nephrotoxic side effects. Analytica Chimica Acta, 2016, 945, 23-30.	2.6	64
54	Enriching screening libraries with bioactive fragment space. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3594-3597.	1.0	95
55	Combining bioinformatics, chemoinformatics and experimental approaches to design chemical probes: Applications in the field of blood coagulation. Annales Pharmaceutiques Francaises, 2016, 74, 253-266.	0.4	2

#	ARTICLE	IF	CITATIONS
56	Safety pharmacology investigations on the nervous system: An industry survey. Journal of Pharmacological and Toxicological Methods, 2016, 81, 37-46.	0.3	57
57	Bioprinting towards Physiologically Relevant Tissue Models for Pharmaceutics. Trends in Biotechnology, 2016, 34, 722-732.	4.9	186
58	Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. Journal of Pharmaceutical and Biomedical Analysis, 2016, 130, 244-263.	1.4	26
59	Compound high-quality criteria: a new vision to guide the development of drugs, current situation. Drug Discovery Today, 2016, 21, 573-584.	3.2	32
60	Irreproducibility in Preclinical Biomedical Research: Perceptions, Uncertainties, and Knowledge Gaps. Trends in Pharmacological Sciences, 2016, 37, 290-302.	4.0	95
61	Transcriptional response networks for elucidating mechanisms of action of multitargeted agents. Drug Discovery Today, 2016, 21, 1063-1075.	3.2	28
62	Molecular inflation, attrition and the rule of five. Advanced Drug Delivery Reviews, 2016, 101, 22-33.	6.6	144
63	Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. Chemical Research in Toxicology, 2016, 29, 564-616.	1.7	148
64	Quantitative structure–retention relationships of flavonoids unraveled by immobilized artificial membrane chromatography. European Journal of Pharmaceutical Sciences, 2016, 88, 147-157.	1.9	10
65	Computational prediction of formulation strategies for beyond-rule-of-5 compounds. Advanced Drug Delivery Reviews, 2016, 101, 6-21.	6.6	129
66	Open Access Could Transform Drug Discovery: A Case Study of JQ1. Expert Opinion on Drug Discovery, 2016, 11, 321-332.	2.5	28
67	High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1717-1727.	1.9	99
68	Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy. Journal of Medicinal Chemistry, 2016, 59, 2841-2846.	2.9	20
69	Discovery of Vibegron: A Potent and Selective β_3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder. Journal of Medicinal Chemistry, 2016, 59, 609-623.	2.9	86
70	One size does not fit all: Challenging some dogmas and taboos in drug discovery. Future Medicinal Chemistry, 2016, 8, 29-38.	1.1	15
71	Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making. Chemical Research in Toxicology, 2016, 29, 452-472.	1.7	24
72	Toxicology Strategies for Drug Discovery: Present and Future. Chemical Research in Toxicology, 2016, 29, 473-504.	1.7	157
73	It takes a team: reflections on insecticide discoveries, toxicological problems and enjoying the unexpected. Pest Management Science, 2017, 73, 666-671.	1.7	9

#	Article	IF	Citations
74	Biophysical properties of the clinical-stage antibody landscape. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 944-949.	3.3	433
75	CADD medicine: design is the potion that can cure my disease. Journal of Computer-Aided Molecular Design, 2017, 31, 249-253.	1.3	9
76	Bringing new dimensions to drug discovery screening: impact of cellular stimulation technologies. Drug Discovery Today, 2017, 22, 1045-1055.	3.2	16
77	Targeting pathogen metabolism without collateral damage to the host. Scientific Reports, 2017, 7, 40406.	1.6	42
78	Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120. Journal of Medicinal Chemistry, 2017, 60, 3124-3153.	2.9	58
79	PatchSearch: A Fast Computational Method for Off-Target Detection. Journal of Chemical Information and Modeling, 2017, 57, 769-777.	2.5	8
80	Drug Design Workshop: A Web-Based Educational Tool To Introduce Computer-Aided Drug Design to the General Public. Journal of Chemical Education, 2017, 94, 335-344.	1.1	39
81	The Opportunities of Metabolomics in Drug Safety Evaluation. Current Pharmacology Reports, 2017, 3, 10-15.	1.5	16
82	New developments in anti-malarial target candidate and product profiles. Malaria Journal, 2017, 16, 26.	0.8	360
83	Emerging RNA editing biomarkers will foster drug development. Drug Discovery Today, 2017, 22, 1056-1063.	3.2	6
84	Validation of Mycobacterium tuberculosis dihydroneopterin aldolase as a molecular target for anti-tuberculosis drug development. Biochemical and Biophysical Research Communications, 2017, 485, 814-819.	1.0	10
85	Human biology-based drug safety evaluation: scientific rationale, current status and future challenges. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 567-574.	1.5	4
86	Monitoring drug–serum protein interactions for early ADME prediction through Surface Plasmon Resonance technology. Journal of Pharmaceutical and Biomedical Analysis, 2017, 144, 188-194.	1.4	37
87	Determination of in Vitro and in Silico Indexes for the Modeling of Blood–Brain Barrier Partitioning of Drugs via Micellar and Immobilized Artificial Membrane Liquid Chromatography. Journal of Medicinal Chemistry, 2017, 60, 3739-3754.	2.9	27
88	Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors. Scientific Reports, 2017, 7, 46277.	1.6	128
89	Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development. Expert Opinion on Drug Discovery, 2017, 12, 733-745.	2.5	3
90	Evolution of Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 234-238.	1.2	34
91	Epigenetic assays for chemical biology and drug discovery. Clinical Epigenetics, 2017, 9, 41.	1.8	25

#	Article	IF	Citations
92	Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective. Regulatory Toxicology and Pharmacology, 2017, 87, S1-S15.	1.3	31
93	3D bioprinting for drug discovery and development in pharmaceutics. Acta Biomaterialia, 2017, 57, 26-46.	4.1	229
94	Integrated Lead Optimization: Translational Models as We Advance Toward the Clinic. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 165-230.	0.2	0
95	Outlook for the Future. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 421-447.	0.2	0
96	Amine promiscuity and toxicology analysis. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 653-657.	1.0	9
97	Challenges in Translational Development of Pharmaceutical Cocrystals. Journal of Pharmaceutical Sciences, 2017, 106, 457-470.	1.6	83
98	The Need for Restructuring the Disordered Science of Amorphous Drug Formulations. Pharmaceutical Research, 2017, 34, 1754-1772.	1.7	71
100	In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach. Drug Discovery Today: Technologies, 2017, 23, 45-52.	4.0	15
101	Hot-Spotting with Thermal Scanning: A Ligand- and Structure-Independent Assessment of Target Ligandability. Journal of Medicinal Chemistry, 2017, 60, 4923-4931.	2.9	18
102	Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases. Journal of Allergy and Clinical Immunology, 2017, 140, 685-687.	1.5	7
103	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2239-2258.	1.0	19
104	Low Data Drug Discovery with One-Shot Learning. ACS Central Science, 2017, 3, 283-293.	5.3	511
105	The ascendance of microphysiological systems to solve the drug testing dilemma. Future Science OA, 2017, 3, FSO0185.	0.9	51
106	The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. Biochemical Pharmacology, 2017, 135, 139-150.	2.0	11
107	Sustainable Practices in Medicinal Chemistry Part 2: Green by Design. Journal of Medicinal Chemistry, 2017, 60, 5955-5968.	2.9	17
108	Bioprinted three dimensional human tissues for toxicology and disease modeling. Drug Discovery Today: Technologies, 2017, 23, 37-44.	4.0	38
109	Networks and Pathways in Systems Pharmacology. SpringerBriefs in Computer Science, 2017, , 11-46.	0.2	4
110	Ligand-Binding Kinetics on Histamine Receptors. Methods in Pharmacology and Toxicology, 2017, , 115-155.	0.1	5

#	Article	IF	Citations
111	From the Cover: High-Throughput Imaging of Cardiac Microtissues for the Assessment of Cardiac Contraction during Drug Discovery. Toxicological Sciences, 2017, 155, 444-457.	1.4	58
112	Species-Dependent Mechanisms of Cardiac Arrhythmia: A Cellular Focus. Clinical Medicine Insights: Cardiology, 2017, 11, 117954681668606.	0.6	64
113	CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens. Scientific Reports, 2017, 7, 13000.	1.6	44
114	Non-clinical efficacy-related studies for human medicines: An overview and retrospective analysis of data for a group of approved medicines. Regulatory Toxicology and Pharmacology, 2017, 91, 249-256.	1.3	1
115	ADMET Evaluation in Drug Discovery. 18. Reliable Prediction of Chemical-Induced Urinary Tract Toxicity by Boosting Machine Learning Approaches. Molecular Pharmaceutics, 2017, 14, 3935-3953.	2.3	66
116	Applying insights from the pharma innovation model to battery commercializationâ€"pros, cons, and pitfalls. MRS Energy & Sustainability, 2017, 4, 1.	1.3	4
117	Charlie Gard and the Limits of Parental Authority. Hastings Center Report, 2017, 47, 15-16.	0.7	10
118	Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administrationâ€"Approved Drugs. Pharmacological Reviews, 2017, 69, 479-496.	7.1	58
119	Potential of small-molecule fungal metabolites in antiviral chemotherapy. Antiviral Chemistry and Chemotherapy, 2017, 25, 20-52.	0.3	31
120	Click and discover. Nature, 2017, 548, 162-164.	13.7	3
121	TIBLE: a web-based, freely accessible resource for small-molecule binding data for mycobacterial species. Database: the Journal of Biological Databases and Curation, 2017, 2017, .	1.4	5
122	Discovery of 2,3â€Dihydroâ€1<i>H</i>â€indene Derivatives as Novel <scp>GPR40</scp> Agonists. Bulletin of the Korean Chemical Society, 2017, 38, 861-868.	1.0	3
123	Exposure-Based Validation of an In Vitro Gastrulation Model for Developmental Toxicity Assays. Toxicological Sciences, 2017, 157, 235-245.	1.4	24
124	Earlyâ€Stage Formulation Considerations. Current Protocols in Chemical Biology, 2017, 9, 306-314.	1.7	2
125	Getting a Handle on Neuropharmacology by Targeting Receptor-Associated Proteins. Neuron, 2017, 96, 989-1001.	3.8	56
126	Parallel Synthesis of 1H-Pyrazolo[3,4-d]pyrimidines via Condensation of N-Pyrazolylamides and Nitriles. ACS Combinatorial Science, 2017, 19, 675-680.	3.8	6
127	A Microfluidic Platform for the Characterisation of CNS Active Compounds. Scientific Reports, 2017, 7, 15692.	1.6	14
128	Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1237-1250.	1.5	15

#	Article	IF	Citations
129	A Review of Recent Advances in Translational Bioinformatics: Bridges from Biology to Medicine. Yearbook of Medical Informatics, 2017, 26, 178-187.	0.8	20
130	Bio-inks for 3D bioprinting: recent advances and future prospects. Polymer Chemistry, 2017, 8, 4451-4471.	1.9	256
131	Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel antiâ€"transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity. Pain, 2017, 158, 660-668.	2.0	50
132	Application of Incident Command Structure to clinical trial management in the academic setting: principles and lessons learned. Trials, 2017, 18, 62.	0.7	2
133	Comprehensive Network Map of ADMEâ€Tox Databases. Molecular Informatics, 2017, 36, 1700029.	1.4	5
134	Mechanisms of Skin Toxicity Associated with Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators. Cell Chemical Biology, 2017, 24, 858-869.e5.	2.5	26
135	Industrial medicinal chemistry insights: neuroscience hit generation at Janssen. Drug Discovery Today, 2017, 22, 1478-1488.	3.2	5
136	Technically Extended MultiParameter Optimization (TEMPO): An Advanced Robust Scoring Scheme To Calculate Central Nervous System Druggability and Monitor Lead Optimization. ACS Chemical Neuroscience, 2017, 8, 147-154.	1.7	30
137	Protein Surface Mimetics: Understanding How Ruthenium Tris(Bipyridines) Interact with Proteins. ChemBioChem, 2017, 18, 223-231.	1.3	15
138	Stem cellâ€"derived models to improve mechanistic understanding and prediction of human drugâ€induced liver injury. Hepatology, 2017, 65, 710-721.	3.6	54
139	Holistic Drug Targeting. , 2017, , 65-88.		7
140	The many roles of molecular complexity in drug discovery. Drug Discovery Today, 2017, 22, 120-126.	3.2	107
141	Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?. British Journal of Pharmacology, 2017, 174, 3749-3765.	2.7	104
142	Scoring of <i>de novo</i> Designed Chemical Entities by Macromolecular Target Prediction. Molecular Informatics, 2017, 36, 1600110.	1.4	5
143	The ChEMBL database in 2017. Nucleic Acids Research, 2017, 45, D945-D954.	6.5	1,718
144	A Novel High Throughput Virtual Screening Protocol to Discover New Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. Chemical and Pharmaceutical Bulletin, 2017, 65, 714-717.	0.6	4
145	â€Parallelized variable selection and modeling based on predictionâ€•algorithm on GPU for feature selection and ADMET model generation. , 2017, , .		1
146	Launch of the Alliance for Human Relevant Science. ATLA Alternatives To Laboratory Animals, 2017, 45, 49-53.	0.7	1

#	Article	IF	Citations
147	The Target Residence Time of Antihistamines Determines Their Antagonism of the G Protein-Coupled Histamine H1 Receptor. Frontiers in Pharmacology, 2017, 8, 667.	1.6	31
148	vNN Web Server for ADMET Predictions. Frontiers in Pharmacology, 2017, 8, 889.	1.6	148
149	An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes. Frontiers in Physiology, 2017, 8, 766.	1.3	64
150	ZeGlobalTox: An Innovative Approach to Address Organ Drug Toxicity Using Zebrafish. International Journal of Molecular Sciences, 2017, 18, 864.	1.8	72
151	Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models. Pharmaceutics, 2017, 9, 41.	2.0	101
152	Drug discovery. , 2017, , 281-420.		1
153	Role of ADME/PK in Drug Discovery, Safety Assessment, and Clinical Development. , 2017, , 1-33.		2
154	Computational Methods in Multitarget Drug Discovery. , 2017, , 239-258.		3
155	Contemporary Considerations for Discovering a Successful Medicine. , 2017, , 560-576.		0
156	Detecting similar binding pockets to enable systems polypharmacology. PLoS Computational Biology, 2017, 13, e1005522.	1.5	35
157	In silico prediction of novel therapeutic targets using gene–disease association data. Journal of Translational Medicine, 2017, 15, 182.	1.8	85
158	Human PK Prediction and Modeling. , 2017, , 51-82.		1
159	Human iPSC Models in Drug Discovery: Opportunities and Challenges. , 2017, , 48-73.		4
160	Predictive Toxicology: Latest Scientific Developments and Their Application in Safety Assessment. , 2017, , 94-115.		3
161	Drug discovery. , 2017, , 183-279.		1
162	Pimping up Drugs Recovered, Superannuated and Under Exploited Drugs - An Introduction to the Basics of Drug Reprofiling. Current Drug Discovery Technologies, 2017, 14, 121-126.	0.6	6
163	Backgrounder. , 2017, , 3-29.		0
164	An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2. Drug Design, Development and Therapy, 2017, Volume 11, 1535-1557.	2.0	6

#	ARTICLE	IF	CITATIONS
165	ADME Optimization in Drug Discovery. , 2017, , 34-44.		2
166	Lessons and Successes in the Use of Molecular Fields. , 2017, , 253-296.		3
167	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. , 2017, , 64-93.		0
168	Unexplored therapeutic opportunities in the human genome. Nature Reviews Drug Discovery, 2018, 17, 317-332.	21.5	263
169	Synthesis and phospholipidosis effect of a series of cationic amphiphilic compounds: a case study to evaluate in silico and in vitro assays. Medicinal Chemistry Research, 2018, 27, 679-692.	1.1	3
170	Comparison of metabolic pathways of different Î±-N-heterocyclic thiosemicarbazones. Analytical and Bioanalytical Chemistry, 2018, 410, 2343-2361.	1.9	12
171	Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications. Chemical Society Reviews, 2018, 47, 3574-3620.	18.7	352
172	The Identification of Pivotal Transcriptional Factors Mediating Cell Responses to Drugs With Drug-Induced Liver Injury Liabilities. Toxicological Sciences, 2018, 162, 177-188.	1.4	6
173	Diclofenac Identified as a Kynurenine 3-Monooxygenase Binder and Inhibitor by Molecular Similarity Techniques. ACS Omega, 2018, 3, 2564-2568.	1.6	11
174	Regulatory pitfalls and opportunities when repurposing for inhalation therapy. Advanced Drug Delivery Reviews, 2018, 133, 57-65.	6.6	17
177	Pharmacokinetics of lipid-drug conjugates loaded into liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 128, 188-199.	2.0	41
178	Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions. Toxicological Sciences, 2018, 163, 655-665.	1.4	140
179	Combination of human acetylcholinesterase and serum albumin sensing surfaces as highly informative analytical tool for inhibitor screening. Journal of Pharmaceutical and Biomedical Analysis, 2018, 155, 177-184.	1.4	12
180	Opportunities and obstacles for deep learning in biology and medicine. Journal of the Royal Society Interface, 2018, 15, 20170387.	1.5	1,282
181	Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. Journal of Medicinal Chemistry, 2018, 61, 6421-6467.	2.9	79
182	Practical application of ligand efficiency metrics in lead optimisation. Bioorganic and Medicinal Chemistry, 2018, 26, 3006-3015.	1.4	44
183	Computer-Aided Drug Design: An Overview. Methods in Molecular Biology, 2018, 1762, 1-19.	0.4	25
184	<i>In Situ</i> Target Engagement Studies in Adherent Cells. ACS Chemical Biology, 2018, 13, 942-950.	1.6	23

#	ARTICLE	IF	CITATIONS
185	Development of novel fluorescent histamine H1-receptor antagonists to study ligand-binding kinetics in living cells. Scientific Reports, 2018, 8, 1572.	1.6	48
186	Inventing new therapies without reinventing the wheel: the power of drug repurposing. British Journal of Pharmacology, 2018, 175, 165-167.	2.7	55
187	Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2018, 9, 1195-1214.	1.7	44
188	The Federal Right to Try Act of 2017â€"A Wrong Turn for Access to Investigational Drugs and the Path Forward. JAMA Internal Medicine, 2018, 178, 321.	2.6	33
189	Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification. Scientific Reports, 2018, 8, 1596.	1.6	30
190	Network-based technologies for early drug discovery. Drug Discovery Today, 2018, 23, 626-635.	3.2	72
191	Synthesis and anticancer activity of novel water soluble benzimidazole carbamates. European Journal of Medicinal Chemistry, 2018, 144, 372-385.	2.6	79
192	Present drug-likeness filters in medicinal chemistry during the hit and lead optimization process: how far can they be simplified?. Drug Discovery Today, 2018, 23, 605-615.	3.2	77
193	Ligandomics: a paradigm shift in biological drug discovery. Drug Discovery Today, 2018, 23, 636-643.	3.2	15
194	Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning. Briefings in Bioinformatics, 2018, 19, 656-678.	3.2	81
195	The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice. Archives of Toxicology, 2018, 92, 1953-1967.	1.9	9
196	Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 457-467.	0.8	15
197	Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations. AAPS Journal, 2018, 20, 46.	2.2	46
199	Adversarial Threshold Neural Computer for Molecular *de Novo* Design. Molecular Pharmaceutics, 2018, 15, 4386-4397.	2.3	153
200	Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge. Methods in Pharmacology and Toxicology, 2018, , 345-364.	0.1	2
201	Noninvasive Preclinical and Clinical Imaging of Liver Transporter Function Relevant to Drug-Induced Liver Injury. Methods in Pharmacology and Toxicology, 2018, , 627-651.	0.1	5
202	Prediction of Human Liver Toxicity Using In Vitro Assays: Limitations and Opportunities. Methods in Pharmacology and Toxicology, 2018, , 125-150.	0.1	5
203	Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies. Scientific Reports, 2018, 8, 4530.	1.6	341

#	ARTICLE	IF	CITATIONS
204	Expanding biological space coverage enhances the prediction of drug adverse effects in human using in vitro activity profiles. Scientific Reports, 2018, 8, 3783.	1.6	39
205	Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity. Pharmacogenomics Journal, 2018, 18, 377-390.	0.9	87
206	Development of Safe Drugs: The hERG Challenge. Medicinal Research Reviews, 2018, 38, 525-555.	5.0	96
207	Three-dimensional cell culture models for anticancer drug screening: Worth the effort?. Journal of Cellular Physiology, 2018, 233, 2993-3003.	2.0	155
208	Stem cell contributions to neurological disease modeling and personalized medicine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 54-62.	2.5	15
209	Next generation organoids for biomedical research and applications. Biotechnology Advances, 2018, 36, 132-149.	6.0	91
210	In Silico Prediction of Compounds Binding to Human Plasma Proteins by QSAR Models. ChemMedChem, 2018, 13, 572-581.	1.6	62
211	Efficacy From Strange Sources. Clinical Pharmacology and Therapeutics, 2018, 103, 253-261.	2.3	8
212	Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nature Reviews Drug Discovery, 2018, 17, 19-33.	21.5	106
213	Modulators of 14-3-3 Protein–Protein Interactions. Journal of Medicinal Chemistry, 2018, 61, 3755-3778.	2.9	202
214	A novel lab-on-a-chip platform for spheroid metabolism monitoring. Cytotechnology, 2018, 70, 375-386.	0.7	26
215	Harnessing the Properties of Natural Products. Annual Review of Pharmacology and Toxicology, 2018, 58, 451-470.	4.2	64
216	Biomechanical regulation of drug sensitivity in an engineered model of human tumor. Biomaterials, 2018, 150, 150-161.	5.7	44
217	Ein Instrumentarium von α–RGD–Integrin–Inhibitoren: Wirkstoffsuche, Herausforderungen und Möglichkeiten. Angewandte Chemie, 2018, 130, 3354-3379.	1.6	12
218	Multi-objective Optimization of Benzamide Derivatives as Rho Kinase Inhibitors. Molecular Informatics, 2018, 37, 1700080.	1.4	6
219	An α–RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities. Angewandte Chemie - International Edition, 2018, 57, 3298-3321.	7.2	94
220	Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. Journal of Medicinal Chemistry, 2018, 61, 2636-2651.	2.9	261
221	Model-Informed Reverse and Forward Translation of Safety Risks in Drug Development. Clinical Pharmacology and Therapeutics, 2018, 103, 199-201.	2.3	2

#	ARTICLE	IF	CITATIONS
222	Intestinal Stem Cells to Advance Drug Development, Precision, and Regenerative Medicine: A Paradigm Shift in Translational Research. AAPS Journal, 2018, 20, 17.	2.2	38
223	Seizure liability assessments using the hippocampal tissue slice: Comparison of non-clinical species. Journal of Pharmacological and Toxicological Methods, 2018, 93, 59-68.	0.3	26
224	Model‐Based Reverse Translation Between Veterinary and Human Medicine: The One Health Initiative. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 65-68.	1.3	23
225	Multiorgan Microphysiological Systems for Drug Development: Strategies, Advances, and Challenges. Advanced Healthcare Materials, 2018, 7, 1701000.	3.9	100
226	Advances in nanomedicine drug delivery applications for HIV therapy. Future Science OA, 2018, 4, FSO230.	0.9	15
227	Industry Perspective on Biomarker Development and Qualification. Clinical Pharmacology and Therapeutics, 2018, 103, 27-31.	2.3	12
228	Working towards New Drugs against Parasitic Worms in a Public-Development Partnership. Trends in Parasitology, 2018, 34, 4-6.	1.5	18
229	ANTIPROLIFERATIVE AND IN SILICO ADMET STUDY OF NEW 4-(PIPERIDIN-1-YLMETHYL)-2- (THIOPHEN-2-YL) QUINOLINE ANALOGUES. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 306.	0.3	5
230	Zebrafish Larvae Are a Suitable Model to Investigate the Metabolic Phenotype of Drug-Induced Renal Tubular Injury. Frontiers in Pharmacology, 2018, 9, 1193.	1.6	13
231	Better science for safer medicines: the human imperative. Journal of the Royal Society of Medicine, 2018, 111, 433-438.	1.1	12
232	Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1315-1330.	1.5	11
234	Using High Content Imaging to Quantify Target Engagement in Adherent Cells. Journal of Visualized Experiments, 2018, , .	0.2	2
235	In Vitro Immune Organs-on-Chip for Drug Development: A Review. Pharmaceutics, 2018, 10, 278.	2.0	54
238	Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. Journal of Translational Medicine, 2018, 16, 304.	1.8	220
239	The challenge of new chemical entities attrition. IBM Journal of Research and Development, 2018, 62, 1:1-1:9.	3.2	0
240	ADMETopt: A Web Server for ADMET Optimization in Drug Design via Scaffold Hopping. Journal of Chemical Information and Modeling, 2018, 58, 2051-2056.	2.5	60
241	Safety Pharmacology Study Results and their Impact on the Design of First-in-human Trials for Authorised Oncology Therapies. Pharmaceutical Medicine, 2018, 32, 335-341.	1.0	0
242	A combined mathematical model linking the formation of amorphous solid dispersions with hot-melt-extrusion process parameters. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 132, 127-145.	2.0	18

#	ARTICLE	IF	CITATIONS
243	Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2018, 61, 9534-9550.	2.9	29
244	Drug discovery and development: Biomarkers of neurotoxicity and neurodegeneration. Experimental Biology and Medicine, 2018, 243, 1037-1045.	1.1	39
245	Using Zebrafish for Investigating the Molecular Mechanisms of Drug-Induced Cardiotoxicity. BioMed Research International, 2018, 2018, 1-10.	0.9	88
246	Investigation of the Nrf2 Stress Response at Cellular Level to Detect Compounds Inducing Oxidative and Electrophilic Stress. Applied in Vitro Toxicology, 2018, 4, 248-264.	0.6	0
247	Modeling the value of predictive affinity scoring in preclinical drug discovery. Current Opinion in Structural Biology, 2018, 52, 103-110.	2.6	14
248	Phenome-wide association studies across large population cohorts support drug target validation. Nature Communications, 2018, 9, 4285.	5.8	134
249	Testing for drug-human serum albumin binding using fluorescent probes and other methods. Expert Opinion on Drug Discovery, 2018, 13, 1005-1014.	2.5	17
250	N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model. Bioorganic and Medicinal Chemistry, 2018, 26, 5169-5180.	1.4	3
251	The future of drug development: the paradigm shift towards systems therapeutics. Drug Discovery Today, 2018, 23, 1990-1995.	3.2	21
252	Methyl-containing pharmaceuticals: Methylation in drug design. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3283-3289.	1.0	77
253	Cinnamoyl-Oxaborole Amides: Synthesis and Their in Vitro Biological Activity. Molecules, 2018, 23, 2038.	1.7	17
254	Pharmacological Properties, Molecular Mechanisms, and Pharmaceutical Development of Asiatic Acid: A Pentacyclic Triterpenoid of Therapeutic Promise. Frontiers in Pharmacology, 2018, 9, 892.	1.6	116
255	The use of human tissue in safety assessment. Journal of Pharmacological and Toxicological Methods, 2018, 93, 29-34.	0.3	3
256	The Impact of Novel Assessment Methodologies in Toxicology on Green Chemistry and Chemical Alternatives. Toxicological Sciences, 2018, 161, 276-284.	1.4	13
257	Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120. European Journal of Medicinal Chemistry, 2018, 154, 367-391.	2.6	35
258	Impact of Cyclodextrin in Drug Delivery System. Sustainable Agriculture Reviews, 2018, , 271-293.	0.6	2
259	A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans. Regulatory Toxicology and Pharmacology, 2018, 96, 94-105.	1.3	111
260	Characterization and Validation of a Human 3D Cardiac Microtissue for the Assessment of Changes in Cardiac Pathology. Scientific Reports, 2018, 8, 10160.	1.6	97

#	Article	IF	Citations
261	Computational Toxicology and Drug Discovery. Methods in Molecular Biology, 2018, 1800, 233-244.	0.4	15
262	Computational Toxicology Methods in Chemical Library Design and High-Throughput Screening Hit Validation. Methods in Molecular Biology, 2018, 1800, 275-285.	0.4	18
263	The current limits in virtual screening and property prediction. Future Medicinal Chemistry, 2018, 10, 1623-1635.	1.1	19
264	Connecting genetics and gene expression data for target prioritisation and drug repositioning. BioData Mining, 2018, 11, 7.	2.2	41
265	Leading-Edge Approaches for InÂVitro Hepatotoxicity Evaluation. , 2018, , 651-712.		0
266	<i>De novo</i> coiled-coil peptides as scaffolds for disrupting proteinâ€"protein interactions. Chemical Science, 2018, 9, 7656-7665.	3.7	36
267	Understanding Key Mechanisms of Exercise-Induced Cardiac Protection to Mitigate Disease: Current Knowledge and Emerging Concepts. Physiological Reviews, 2018, 98, 419-475.	13.1	120
268	Human liver spheroids in chemically defined conditions for studies of geneâ€"drug, drugâ€"drug and diseaseâ€"drug interactions. Pharmacogenomics, 2018, 19, 1133-1138.	0.6	13
269	Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline. Frontiers in Pharmacology, 2018, 9, 703.	1.6	78
270	Exploring Polypharmacology in Drug Design. Methods in Molecular Biology, 2018, 1824, 229-243.	0.4	7
271	Potential Use of Stem Cells in Mood Disorders. Advances in Experimental Medicine and Biology, 2018, 1089, 87-96.	0.8	2
272	Lead-like Drugs: A Perspective. Journal of Medicinal Chemistry, 2018, 61, 10375-10384.	2.9	41
273	3D bioprinting of tissues and organs for regenerative medicine. Advanced Drug Delivery Reviews, 2018, 132, 296-332.	6.6	417
274	Docking techniques in pharmacology: How much promising?. Computational Biology and Chemistry, 2018, 76, 210-217.	1.1	117
275	pH-permeability profiles for drug substances: Experimental detection, comparison with human intestinal absorption and modelling. European Journal of Pharmaceutical Sciences, 2018, 123, 429-440.	1.9	26
276	Expert perspectives on potential environmental risks from nanomedicines and adequacy of the current guideline on environmental risk assessment. Environmental Science: Nano, 2018, 5, 1873-1889.	2.2	30
277	How medicinal chemists learned about log P. Journal of Computer-Aided Molecular Design, 2018, 32, 809-819.	1.3	7
278	Electrohydrodynamic atomization and spray-drying for the production of pure drug nanocrystals and co-crystals. Advanced Drug Delivery Reviews, 2018, 131, 79-100.	6.6	47

#	Article	IF	Citations
279	In vitro screening of cell bioenergetics to assess mitochondrial dysfunction in drug development. Toxicology in Vitro, 2018, 52, 374-383.	1.1	11
280	Outâ€compute drug side effects: Focus on cytochrome P450 2D6 modeling. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2018, 8, e1366.	6.2	9
281	A transcriptome comparison of time-matched developing human, mouse and rat neural progenitor cells reveals human uniqueness. Toxicology and Applied Pharmacology, 2018, 354, 40-55.	1.3	28
282	Establishment of a quantitative bioanalytical method for an acetylcholinesterase inhibitor Ethyl characterization and in vitro metabolite profiling using Liquid Chromatography-Mass Spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1096, 214-222.	1.2	12
283	Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective. Clinical Pharmacology and Therapeutics, 2018, 104, 916-932.	2.3	80
284	Rapid identification of antimicrometastases drugs using integrated model systems with two dimensional monolayer, three dimensional spheroids, and zebrafish xenotransplantation tumors. Biotechnology and Bioengineering, 2018, 115, 2828-2843.	1.7	16
285	Applications of tumor chip technology. Lab on A Chip, 2018, 18, 2893-2912.	3.1	86
286	Geometric Deep Learning Autonomously Learns Chemical Features That Outperform Those Engineered by Domain Experts. Molecular Pharmaceutics, 2018, 15, 4371-4377.	2.3	42
287	The fruit fly Drosophila melanogaster as an innovative preclinical ADME model for solute carrier membrane transporters, with consequences for pharmacology and drug therapy. Drug Discovery Today, 2018, 23, 1746-1760.	3.2	10
288	Developments in toxicogenomics: understanding and predicting compound-induced toxicity from gene expression data. Molecular Omics, 2018, 14, 218-236.	1.4	90
289	Identification of Nontoxic Substructures: A New Strategy to Avoid Potential Toxicity Risk. Toxicological Sciences, 2018, 165, 396-407.	1.4	16
290	Translational in vitro research: integrating 3D drug discovery and development processes into the drug development pipeline. Drug Discovery Today, 2019, 24, 26-30.	3.2	26
291	Predicting Human Pharmacokinetics: Physiologically Based Pharmacokinetic Modeling and In Silico ADME Prediction in Early Drug Discovery. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 135-137.	0.6	8
292	Pharmaceutical perspective on the translational hurdles of phytoconstituents and strategies to overcome. Journal of Drug Delivery Science and Technology, 2019, 53, 101201.	1.4	25
293	Medicine in the Fourth Dimension. Cell Metabolism, 2019, 30, 238-250.	7.2	245
294	Organs-on-Chips: a new paradigm for safety assessment of drug-induced thrombosis. Current Opinion in Toxicology, 2019, 17, 1-8.	2.6	2
295	Animal to human translation: a systematic scoping review of reported concordance rates. Journal of Translational Medicine, 2019, 17, 223.	1.8	170
296	Systems biology and network pharmacology of frailty reveal novel epigenetic targets and mechanisms. Scientific Reports, 2019, 9, 10593.	1.6	6

#	Article	IF	Citations
297	Identification of Novel Trypanosoma cruzi Proteasome Inhibitors Using a Luminescence-Based High-Throughput Screening Assay. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	18
298	Preparation, characterization, inÂvitro and inÂvivo evaluation of metronidazoleâ€"gallic acid cocrystal: A combined experimental and theoretical investigation. Journal of Molecular Structure, 2019, 1197, 727-735.	1.8	17
299	Combined Ensemble Docking and Machine Learning in Identification of Therapeutic Agents with Potential Inhibitory Effect on Human CES1. Molecules, 2019, 24, 2747.	1.7	6
300	Identification of novel inhibitors for TNFÎ±, TNFR1 and TNFÎ±-TNFR1 complex using pharmacophore-based approaches. Journal of Translational Medicine, 2019, 17, 215.	1.8	64
301	Workshop Report. Circulation Research, 2019, 125, 855-867.	2.0	53
302	The Bloodâ€"Brain Barrier (BBB) Score. Journal of Medicinal Chemistry, 2019, 62, 9824-9836.	2.9	157
303	The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method. Frontiers in Pharmacology, 2019, 10, 1171.	1.6	32
304	MitoToxy assay: A novel cell-based method for the assessment of metabolic toxicity in a multiwell plate format using a lactate FRET nanosensor, Laconic. PLoS ONE, 2019, 14, e0224527.	1.1	12
305	Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Research, 2020, 48, D1031-D1041.	6.5	488
306	Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. Frontiers in Pharmacology, 2019, 10, 1235.	1.6	24
307	Elucidating Compound Mechanism of Action and Predicting Cytotoxicity Using Machine Learning Approaches, Taking Prediction Confidence into Account. Current Protocols in Chemical Biology, 2019, 11, e73.	1.7	1
308	Deep Transferable Compound Representation across Domains and Tasks for Low Data Drug Discovery. Journal of Chemical Information and Modeling, 2019, 59, 4528-4539.	2.5	31
309	The NIH microphysiological systems program: developing in vitro tools for safety and efficacy in drug development. Current Opinion in Pharmacology, 2019, 48, 146-154.	1.7	34
310	Mechanisms of Chronic Fialuridine Hepatotoxicity as Revealed in Primary Human Hepatocyte Spheroids. Toxicological Sciences, 2019, 171, 385-395.	1.4	19
311	Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway. Biochemical Pharmacology, 2019, 169, 113610.	2.0	30
312	Predicting and Experimentally Validating Hot-Spot Residues at Proteinâ€"Protein Interfaces. ACS Chemical Biology, 2019, 14, 2252-2263.	1.6	54
313	Cyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors. Translational Oncology, 2019, 12, 404-416.	1.7	16
314	Strategies to optimize drug half-life in lead candidate identification. Expert Opinion on Drug Discovery, 2019, 14, 221-230.	2.5	14

#	Article	IF	Citations
315	Tyrosinase and Î±-glucosidase inhibitory potential of compounds isolated from Quercus coccifera bark: In vitro and in silico perspectives. Bioorganic Chemistry, 2019, 86, 296-304.	2.0	32
316	Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT$_{1A}$ Receptor-Biased Agonists with Robust Antidepressant-like Activity. Journal of Medicinal Chemistry, 2019, 62, 2750-2771.	2.9	21
317	Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update. Pharmaceutics, 2019, 11, 41.	2.0	111
318	Liver safety evaluation of endothelin receptor antagonists using HepatoPac Â® : A single model impact assessment on hepatocellular health, function and bile acid disposition. Journal of Applied Toxicology, 2019, 39, 1192-1207.	1.4	8
319	hERG optimizations of IMB1603, discovery of alternative benzothiazinones as new antitubercular agents. European Journal of Medicinal Chemistry, 2019, 179, 208-217.	2.6	13
320	Lens cholesterol biosynthesis inhibition: A common mechanism of cataract formation in laboratory animals by pharmaceutical products. Journal of Applied Toxicology, 2019, 39, 1348-1361.	1.4	5
321	Novel 2-mercapto imidazole and triazole derivatives as potent TGR5 receptor agonists. Medicine in Drug Discovery, 2019, 1, 100002.	2.3	6
322	Exploring the Chemical Space of Cytochrome P450 Inhibitors Using Integrated Physicochemical Parameters, Drug Efficiency Metrics and Decision Tree Models. Computation, 2019, 7, 26.	1.0	3
323	Plasma Protein Binding as an Optimizable Parameter for Acidic Drugs. Drug Metabolism and Disposition, 2019, 47, 865-873.	1.7	19
324	Genetic Insights for Drug Development in NAFLD. Trends in Pharmacological Sciences, 2019, 40, 506-516.	4.0	52
325	Leveraging heterogeneous data from GHS toxicity annotations, molecular and protein target descriptors and Tox21 assay readouts to predict and rationalise acute toxicity. Journal of Cheminformatics, 2019, 11, 36.	2.8	6
326	Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?. Journal of Medicinal Chemistry, 2019, 62, 10026-10043.	2.9	52
327	GPCR drug discovery-moving beyond the orthosteric to the allosteric domain. Advances in Pharmacology, 2019, 86, 1-20.	1.2	14
328	Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery. IScience, 2019, 15, 291-306.	1.9	27
329	Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. Molecules, 2019, 24, 1855.	1.7	68
330	Drugâ€"Target Association Kinetics in Drug Discovery. Trends in Biochemical Sciences, 2019, 44, 861-871.	3.7	42
331	Qualifying X-ray and Stimulated Raman Spectromicroscopy for Mapping Cutaneous Drug Penetration. Analytical Chemistry, 2019, 91, 7208-7214.	3.2	12
332	Functional transepithelial transport measurements to detect nephrotoxicity in vitro using the RPTEC/TERT1 cell line. Archives of Toxicology, 2019, 93, 1965-1978.	1.9	21

#	Article	IF	Citations
333	Designer receptor technology for the treatment of epilepsy. EBioMedicine, 2019, 43, 641-649.	2.7	38
334	Drug safety Africa: An overview of safety pharmacology & toxicology in South Africa. Journal of Pharmacological and Toxicological Methods, 2019, 98, 106579.	0.3	1
335	Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics. Science Advances, 2019, 5, eaaw1567.	4.7	44
336	Antitrypanosomal Activity of Acetogenins Isolated from the Seeds of *Porcelia macrocarpa* Is Associated with Alterations in Both Plasma Membrane Electric Potential and Mitochondrial Membrane Potential. Journal of Natural Products, 2019, 82, 1177-1182.	1.5	12
337	Computational Molecular Modeling of Pin1 Inhibition Activity of Quinazoline, Benzophenone, and Pyrimidine Derivatives. Journal of Chemistry, 2019, 2019, 1-11.	0.9	9
338	Utility of Chimeric Mice with Humanized Liver for Predicting Human Pharmacokinetics in Drug Discovery: Comparison with *in Vitro*–*in Vivo* Extrapolation and Allometric Scaling. Biological and Pharmaceutical Bulletin, 2019, 42, 327-336.	0.6	14
339	A guide to tumor assessment methodologies in cancer drug discovery. , 2019, , 233-248.		1
340	The compromise of virtual screening and its impact on drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 619-637.	2.5	59
341	ADMET modeling approaches in drug discovery. Drug Discovery Today, 2019, 24, 1157-1165.	3.2	333
342	Using Human Genetics to Drive Drug Discovery: A Perspective. American Journal of Kidney Diseases, 2019, 74, 111-119.	2.1	7
343	Repurposed Molecules: A New Hope in Tackling Neglected Infectious Diseases. , 2019, , 119-160.		9
344	Real-Time, *in Vivo* Correlation of Molecular Structure with Drug Distribution in the Brain Striatum Following Convection Enhanced Delivery. ACS Chemical Neuroscience, 2019, 10, 2287-2298.	1.7	25
345	The FICI paradigm: Correcting flaws in antimicrobial in vitro synergy screens at their inception. Biochemical Pharmacology, 2019, 163, 299-307.	2.0	33
346	Drug repurposing for antimicrobial discovery. Nature Microbiology, 2019, 4, 565-577.	5.9	217
347	Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide. Future Medicinal Chemistry, 2019, 11, 489-493.	1.1	29
348	One Drug Multiple Targets: An Approach To Predict Drug Efficacies on Bacterial Strains Differing in Membrane Composition. ACS Omega, 2019, 4, 4977-4983.	1.6	6
349	Safety biomarker applications in drug development. Journal of Toxicological Sciences, 2019, 44, 225-235.	0.7	11
350	Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects. Nature Communications, 2019, 10, 1579.	5.8	61

#	Article	IF	Citations
351	Derivation of adult canine intestinal organoids for translational research in gastroenterology. BMC Biology, 2019, 17, 33.	1.7	82
352	A live cell NanoBRET binding assay allows the study of ligand-binding kinetics to the adenosine A3 receptor. Purinergic Signalling, 2019, 15, 139-153.	1.1	35
353	Functional-genetic approaches to understanding drug response and resistance. Current Opinion in Genetics and Development, 2019, 54, 41-47.	1.5	3
354	Logistic Classification Models for pH–Permeability Profile: Predicting Permeability Classes for the Biopharmaceutical Classification System. Journal of Chemical Information and Modeling, 2019, 59, 2442-2455.	2.5	14
355	Entry of therapeutics into the brain: Influence of exposed polarity calculated in silico and measured in vitro by supercritical fluid chromatography. International Journal of Pharmaceutics, 2019, 560, 294-305.	2.6	10
356	Next-Generation Compound Delivery Platforms to Support Miniaturized Biology. SLAS Technology, 2019, 24, 245-255.	1.0	2
357	Automated De Novo Drug Design: Are We Nearly There Yet?. Angewandte Chemie - International Edition, 2019, 58, 10792-10803.	7.2	99
358	A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. Scientific Reports, 2019, 9, 1407.	1.6	61
359	Automated De Novo Drug Design: Are We Nearly There Yet?. Angewandte Chemie, 2019, 131, 10906-10917.	1.6	12
360	Binding kinetics of ligands acting at GPCRs. Molecular and Cellular Endocrinology, 2019, 485, 9-19.	1.6	79
361	Prediction of Active Drug Molecule using Back-Propagation Neural Network. , 2019, , .		2
362	NMR spectroscopy in drug discovery and development: Evaluation of physico-chemical properties. ADMET and DMPK, 2019, 7, 242-251.	1.1	6
363	A Comparative Study of Naive Bayes and k-NN Algorithm for Multi-class Drug Molecule Classification. , 2019, , .		4
364	Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles. Translational Medicine Communications, 2019, 4, .	0.5	299
365	An Improved Free Energy Perturbation FEP+ Sampling Protocol for Flexible Ligand-Binding Domains. Scientific Reports, 2019, 9, 16829.	1.6	48
366	Undersampling: case studies of flaviviral inhibitory activities. Journal of Computer-Aided Molecular Design, 2019, 33, 997-1008.	1.3	6
368	CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, Parkinson's disease and spasticity. Neuropharmacology, 2019, 147, 4-10.	2.0	17
369	Future Needs in Issue Resolution of Problems That Arise in Drug Development. , 2019, , 303-338.		0

#	Article	IF	Citations
370	Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals. SLAS Discovery, 2019, 24, 1-24.	1.4	42
371	Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs. Journal of Medicinal Chemistry, 2019, 62, 1701-1714.	2.9	286
372	Application of complex in vitro models (CIVMs) in drug discovery for safety testing and disease modeling. , 2019, , 121-158.		5
373	Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development. Journal of Medicinal Chemistry, 2019, 62, 665-687.	2.9	23
374	Identification of factors associated with first-cycle drug approval rates and regulatory outcomes for new drug applications. Pharmacological Research, 2019, 139, 166-172.	3.1	3
375	Impact of dosing schedule in animal experiments on compound progression decisions. Drug Discovery Today, 2019, 24, 371-376.	3.2	3
376	Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672. ACS Medicinal Chemistry Letters, 2019, 10, 300-305.	1.3	14
377	A simple model to solve a complex drug toxicity problem. Toxicology Research, 2019, 8, 157-171.	0.9	16
378	Predicting Ames Mutagenicity Using Conformal Prediction in the Ames/QSAR International Challenge Project. Mutagenesis, 2019, 34, 33-40.	1.0	13
379	Machine Learning Models for the Prediction of Chemotherapy-Induced Peripheral Neuropathy. Pharmaceutical Research, 2019, 36, 35.	1.7	17
380	Using human experience to identify drug repurposing opportunities: theory and practice. British Journal of Clinical Pharmacology, 2019, 85, 680-689.	1.1	13
382	A rapid method for post-antibiotic bacterial susceptibility testing. PLoS ONE, 2019, 14, e0210534.	1.1	22
383	Safety Assessment of Pharmaceuticals. , 2019, , 167-176.		1
384	Today's Challenges to De-Risk and Predict Drug Safety in Human "Mind-the-Gap". Toxicological Sciences, 2019, 167, 307-321.	1.4	78
385	A Practical Guide to the Design of Molecular Crystals. Crystal Growth and Design, 2019, 19, 1426-1453.	1.4	222
386	Synthesis of a 6-Aza-Isoindolinone-Based Inhibitor of Phosphoinositide 3-Kinase Î³ via Ruthenium-Catalyzed [2 + 2 + 2] Cyclotrimerization. ACS Medicinal Chemistry Letters, 2019, 10, 117-120.	1.3	5
387	Isolation and in silico prediction of potential drug-like compounds from Anethum sowa L. root extracts targeted towards cancer therapy. Computational Biology and Chemistry, 2019, 78, 242-259.	1.1	14
388	Advances in Lead Generation. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 517-524.	1.0	25

#	ARTICLE	IF	CITATIONS
389	Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery, 2019, 18, 41-58.	21.5	2,689
390	Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting. Advanced Drug Delivery Reviews, 2019, 140, 129-135.	6.6	20
391	Cardiovascular disease models: A game changing paradigm in drug discovery and screening. Biomaterials, 2019, 198, 3-26.	5.7	149
392	Current trends in <i>in silico</i>, <i>in vitro</i> toxicology, and safety biomarkers in early drug development. Drug and Chemical Toxicology, 2019, 42, 113-121.	1.2	21
393	Should the United States government regulate prescription prices? A critical review. Research in Social and Administrative Pharmacy, 2020, 16, 717-723.	1.5	5
394	Human pluripotent stem cellâ€"derived models and drug screening in CNS precision medicine. Annals of the New York Academy of Sciences, 2020, 1471, 18-56.	1.8	54
395	Big Data and Artificial Intelligence Modeling for Drug Discovery. Annual Review of Pharmacology and Toxicology, 2020, 60, 573-589.	4.2	209
396	Moving beyond Binary Predictions of Human Drug-Induced Liver Injury (DILI) toward Contrasting Relative Risk Potential. Chemical Research in Toxicology, 2020, 33, 223-238.	1.7	49
397	Kinetics of ligand binding and signaling. , 2020, , 171-194.		2
398	Use of Zebrafish in Drug Discovery Toxicology. Chemical Research in Toxicology, 2020, 33, 95-118.	1.7	315
399	New role for crinamine as a potent, safe and selective inhibitor of human monoamine oxidase B: In vitro and in silico pharmacology and modeling. Journal of Ethnopharmacology, 2020, 248, 112305.	2.0	16
400	The Symbiotic Relationship Between Drug Discovery and Organic Chemistry. Chemistry - A European Journal, 2020, 26, 1196-1237.	1.7	97
401	Targeting B7â€‹1 in immunotherapy. Medicinal Research Reviews, 2020, 40, 654-682.	5.0	44
402	Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity. Chemical Research in Toxicology, 2020, 33, 154-161.	1.7	9
403	A 3D Heterotypic Multicellular Tumor Spheroid Assay Platform to Discriminate Drug Effects on Stroma versus Cancer Cells. SLAS Discovery, 2020, 25, 265-276.	1.4	16
404	Modifying the lipophilic part of phenylthiazole antibiotics to control their drug-likeness. European Journal of Medicinal Chemistry, 2020, 185, 111830.	2.6	20
405	Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies. Journal of Medicinal Chemistry, 2020, 63, 6251-6275.	2.9	12
406	Key indicators of phase transition for clinical trials through machine learning. Drug Discovery Today, 2020, 25, 414-421.	3.2	26

#	Article	IF	Citations
407	Multiscale modelling of drug mechanism and safety. Drug Discovery Today, 2020, 25, 519-534.	3.2	15
408	In Silico Design and Analysis of a Kinase-Focused Combinatorial Library Considering Diversity and Quality. Journal of Chemical Information and Modeling, 2020, 60, 92-107.	2.5	7
409	Quantitative Systems Toxicology Modeling To Address Key Safety Questions in Drug Development: A Focus of the TransQST Consortium. Chemical Research in Toxicology, 2020, 33, 7-9.	1.7	14
410	Mechanisms of increased bioavailability through amorphous solid dispersions: a review. Drug Delivery, 2020, 27, 110-127.	2.5	185
411	From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis. Lancet Rheumatology, The, 2020, 2, e50-e62.	2.2	17
412	Tissue Chips in Space: Modeling Human Diseases in Microgravity. Pharmaceutical Research, 2020, 37, 8.	1.7	40
413	Is there enough focus on lipophilicity in drug discovery?. Expert Opinion on Drug Discovery, 2020, 15, 261-263.	2.5	60
414	Application and Impact of Human Dose Projection from Discovery to Early Drug Development. AAPS PharmSciTech, 2020, 21, 44.	1.5	1
415	Advanced microtechnologies for high-throughput screening. , 2020, , 149-175.		1
416	Utilizing Stimulated Raman Scattering Microscopy To Study Intracellular Distribution of Label-Free Ponatinib in Live Cells. Journal of Medicinal Chemistry, 2020, 63, 2028-2034.	2.9	50
417	Log$D$ Contributions of Substituents Commonly Used in Medicinal Chemistry. ACS Medicinal Chemistry Letters, 2020, 11, 72-76.	1.3	34
418	The contribution of multicellular model organisms to neuronal ceroid lipofuscinosis research. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165614.	1.8	22
419	Fluorescent ligands: Bringing light to emerging GPCR paradigms. British Journal of Pharmacology, 2020, 177, 978-991.	2.7	52
420	Evaluation of the anti-inflammatory effects of synthesised tanshinone I and isotanshinone I analogues in zebrafish. PLoS ONE, 2020, 15, e0240231.	1.1	7
421	A design-thinking approach to therapeutic translation: tympanic regeneration. Current Opinion in Otolaryngology and Head and Neck Surgery, 2020, 28, 274-280.	0.8	1
422	Utility of Three-Dimensional Cultures of Primary Human Hepatocytes (Spheroids) as Pharmacokinetic Models. Biomedicines, 2020, 8, 374.	1.4	19
423	Engineered tissues and strategies to overcome challenges in drug development. Advanced Drug Delivery Reviews, 2020, 158, 116-139.	6.6	26
424	Pharmaceutical technologies with potential application to insecticide discovery â€. Pest Management Science, 2020, 77, 3617-3625.	1.7	8

#	Article	IF	Citations
425	New Salt and Cocrystal of Mequitazine: Impact of Coformer Flexibility and Hydrogen Bond Donors on Polymorphism. Crystal Growth and Design, 2020, 20, 7219-7229.	1.4	5
426	Fragment-based target screening as an empirical approach to prioritising targets: a case study on antibacterials. Drug Discovery Today, 2020, 25, 2030-2037.	3.2	10
427	Organotypic Models to Study Human Glioblastoma: Studying the Beast in Its Ecosystem. IScience, 2020, 23, 101633.	1.9	12
428	Quantifying the probability of pharmacological success to inform compound progression decisions. PLoS ONE, 2020, 15, e0240234.	1.1	4
429	Teaching of Biopharmaceutics in a Drug Design Course: Use of GastroPlus as Educational Software. Journal of Chemical Education, 2020, 97, 2212-2220.	1.1	13
430	Generative Network Complex for the Automated Generation of Drug-like Molecules. Journal of Chemical Information and Modeling, 2020, 60, 5682-5698.	2.5	79
431	A Tiered Female Ovarian Toxicity Screening Identifies Toxic Effects of Checkpoint Kinase 1 Inhibitors on Murine Growing Follicles. Toxicological Sciences, 2020, 177, 405-419.	1.4	7
432	Predictive and translational models for renal drug safety evaluation. , 2020, , 507-534.		0
433	Synthesis, biochemical and histological study of captopril derivatives as a possible drug for diabetes. AIP Conference Proceedings, 2020, , .	0.3	0
434	Reprogramming of antibiotics to combat antimicrobial resistance. Archiv Der Pharmazie, 2020, 353, e2000168.	2.1	15
435	Challenges and opportunities to include patientâ€‹centric product design in industrial medicines development to improve therapeutic goals. British Journal of Clinical Pharmacology, 2020, 86, 2020-2027.	1.1	14
437	Fsp3: A new parameter for drug-likeness. Drug Discovery Today, 2020, 25, 1839-1845.	3.2	156
438	Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opinion on Drug Discovery, 2020, 15, 1473-1487.	2.5	99
439	Synthesis and biological screening of a library of macamides as TNF-Î± inhibitors. RSC Medicinal Chemistry, 2020, 11, 1196-1209.	1.7	2
440	Practical guide on MALDI-TOF MS method development for high throughput profiling of pharmaceutically relevant, small molecule chemical reactions. Tetrahedron, 2020, 76, 131434.	1.0	13
441	Biomimetic Artificial Membrane Permeability Assay over Franz Cell Apparatus Using BCS Model Drugs. Pharmaceutics, 2020, 12, 988.	2.0	12
442	COSMO-RS-Based Descriptors for the Machine Learning-Enabled Screening of Nucleotide Analogue Drugs against SARS-CoV-2. Journal of Physical Chemistry Letters, 2020, 11, 9408-9414.	2.1	10
443	Optimization of kinetic stabilizers of tetrameric transthyretin: A prospective ligand efficiency-guided approach. Bioorganic and Medicinal Chemistry, 2020, 28, 115794.	1.4	4

#	Article	IF	Citations
444	Synthesis and Biological Application of Polylactic Acid. Molecules, 2020, 25, 5023.	1.7	198
445	Off-Patent Drug Repositioning. Journal of Chemical Information and Modeling, 2020, 60, 5746-5753.	2.5	14
446	Human iPSC‐Derived Blood‐Brain Barrier Models: Valuable Tools for Preclinical Drug Discovery and Development?. Current Protocols in Stem Cell Biology, 2020, 55, e122.	3.0	26
447	<i>De Novo</i> Drug Design of Targeted Chemical Libraries Based on Artificial Intelligence and Pair-Based Multiobjective Optimization. Journal of Chemical Information and Modeling, 2020, 60, 4582-4593.	2.5	55
448	Response to and recovery from treatment in human liver-mimetic clinostat spheroids: a model for assessing repeated-dose drug toxicity. Toxicology Research, 2020, 9, 379-389.	0.9	6
449	Tissue-specific genetic features inform prediction of drug side effects in clinical trials. Science Advances, 2020, 6, .	4.7	33
450	How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development. Handbook of Experimental Pharmacology, 2020, 265, 29-56.	0.9	3
451	Drug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones. PLoS Computational Biology, 2020, 16, e1008106.	1.5	11
452	Public perception of laboratory animal testing: Historical, philosophical, and ethical view. Addiction Biology, 2021, 26, e12991.	1.4	17
453	Artificial intelligence in the pharmaceutical sector: current scene and future prospect. , 2020, , 73-107.		16
454	Twenty years of safety pharmacology model validation and the wider implications of this to drug discovery. Journal of Pharmacological and Toxicological Methods, 2020, 105, 106912.	0.3	2
455	ADME Prediction with KNIME: Development and Validation of a Publicly Available Workflow for the Prediction of Human Oral Bioavailability. Journal of Chemical Information and Modeling, 2020, 60, 2660-2667.	2.5	31
456	Psychiatric Drug Discovery and Development. , 2020, , 35-68.		2
457	Dual Transcriptomic and Molecular Machine Learning Predicts all Major Clinical Forms of Drug Cardiotoxicity. Frontiers in Pharmacology, 2020, 11, 639.	1.6	15
458	In silico prediction of drug-induced liver injury: Quo vadis?. Advances in Molecular Toxicology, 2020, 13, 31-68.	0.4	0
459	Advances in the study of drug metabolism – symposium report of the 12th Meeting of the International Society for the Study of Xenobiotics (ISSX). Drug Metabolism Reviews, 2020, 52, 395-407.	1.5	8
460	Predicting drug properties with parameter-free machine learning: pareto-optimal embedded modeling (POEM). Machine Learning: Science and Technology, 2020, 1, 025008.	2.4	9
461	Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure–Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H₁ Receptor Inverse Agonist. Journal of Medicinal Chemistry, 2020, 63, 7268-7292.	2.9	21

#	ARTICLE	IF	CITATIONS
462	CRISPR Meets Zebrafish: Accelerating the Discovery of New Therapeutic Targets. SLAS Discovery, 2020, 25, 552-567.	1.4	14
463	Image-based high-content screening in drug discovery. Drug Discovery Today, 2020, 25, 1348-1361.	3.2	52
464	Discovering and validating cancer genetic dependencies: approaches and pitfalls. Nature Reviews Genetics, 2020, 21, 671-682.	7.7	41
465	PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures. BMC Bioinformatics, 2020, 21, 231.	1.2	11
466	Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies. Journal of Medicinal Chemistry, 2020, 63, 11397-11419.	2.9	55
467	Porcine cancer models: potential tools to enhance cancer drug trials. Expert Opinion on Drug Discovery, 2020, 15, 893-902.	2.5	8
468	Microphysiological Systems: A Pathologist's Perspective. Veterinary Pathology, 2020, 57, 358-368.	0.8	4
469	Quantitative Transcriptional Biomarkers of Xenobiotic Receptor Activation in Rat Liver for the Early Assessment of Drug Safety Liabilities. Toxicological Sciences, 2020, 175, 98-112.	1.4	20
470	Multiobjective de novo drug design with recurrent neural networks and nondominated sorting. Journal of Cheminformatics, 2020, 12, 14.	2.8	50
471	Multiparametric Assays for Accelerating Early Drug Discovery. Trends in Pharmacological Sciences, 2020, 41, 318-335.	4.0	14
472	A map of the amine–carboxylic acid coupling system. Nature, 2020, 580, 71-75.	13.7	67
473	In silico toxicology: From structure–activity relationships towards deep learning and adverse outcome pathways. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2020, 10, e1475.	6.2	80
474	Hydrostatic pressure regulates CYP1A2 expression in human hepatocytes via a mechanosensitive aryl hydrocarbon receptor-dependent pathway. American Journal of Physiology - Cell Physiology, 2020, 318, C889-C902.	2.1	8
475	Ahp-Cyclodepsipeptide Inhibitors of Elastase: Lyngbyastatin 7 Stability, Scalable Synthesis, and Focused Library Analysis. ACS Medicinal Chemistry Letters, 2020, 11, 419-425.	1.3	5
476	Development of an adverse drug event network to predict drug toxicity. Current Research in Toxicology, 2020, 1, 48-55.	1.3	5
477	Roughened graphite biointerfaced with P450 liver microsomes: Surface and electrochemical characterizations. Colloids and Surfaces B: Biointerfaces, 2020, 189, 110790.	2.5	10
478	Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation. Journal of Medicinal Chemistry, 2020, 63, 1724-1749.	2.9	31
479	Pluripotent-Stem-Cell-Derived Hepatic Cells: Hepatocytes and Organoids for Liver Therapy and Regeneration. Cells, 2020, 9, 420.	1.8	61

#	ARTICLE	IF	CITATIONS
480	Entering the era of computationally driven drug development. Drug Metabolism Reviews, 2020, 52, 283-298.	1.5	25
481	Striking essential oil: tapping into a largely unexplored source for drug discovery. Scientific Reports, 2020, 10, 2867.	1.6	17
482	Cerebrospinal Fluid Characterization in Cynomolgus Monkeys, Beagle Dogs, and GÃ¶ttingen Minipigs. International Journal of Toxicology, 2020, 39, 124-130.	0.6	4
483	Biomarkers of genome instability in normal mammalian genomes following drugâ€induced replication stress. Environmental and Molecular Mutagenesis, 2020, 61, 770-785.	0.9	5
484	Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation. Regulatory Toxicology and Pharmacology, 2020, 113, 104624.	1.3	22
485	Discovery of <i>N</i>-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 414-418.	1.3	28
486	Chemogenetics a robust approach to pharmacology and gene therapy. Biochemical Pharmacology, 2020, 175, 113889.	2.0	21
487	Modeling Physico-Chemical ADMET Endpoints with Multitask Graph Convolutional Networks. Molecules, 2020, 25, 44.	1.7	67
488	Mechanistic insights into effect of surfactants on oral bioavailability of amorphous solid dispersions. Journal of Controlled Release, 2020, 320, 214-225.	4.8	38
489	Utility of Physicochemical Properties for the Prediction of Toxicological Outcomes: Takeda Perspective. ACS Medicinal Chemistry Letters, 2020, 11, 203-209.	1.3	23
490	A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies. Lab on A Chip, 2020, 20, 468-476.	3.1	25
491	Domain-adversarial multi-task framework for novel therapeutic property prediction of compounds. Bioinformatics, 2020, 36, 2848-2855.	1.8	8
492	Functional analysis and screening small molecules to RpfF protein in Xanthomonas oryzae involved in rice bacterial blight disease. Journal of Integrative Agriculture, 2020, 19, 735-747.	1.7	9
493	The Deep Genome Project. Genome Biology, 2020, 21, 18.	3.8	30
494	Hepatotoxicity Modeling Using Counter-Propagation Artificial Neural Networks: Handling an Imbalanced Classification Problem. Molecules, 2020, 25, 481.	1.7	13
495	Revealing cytotoxic substructures in molecules using deep learning. Journal of Computer-Aided Molecular Design, 2020, 34, 731-746.	1.3	33
496	Syntheses and pharmacokinetic evaluations of four metabolites of 2-(4-(2-((1H-benzo[d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)-N-(6-methyl-2,4-bis-(methylthio)pyridin-3-yl)acetamide hydrochloride [K-604], an acyl-CoA:cholesterol O-acyltransferase-1 inhibitor. Bioorganic and Medicinal Chemistry, 2020, 28, 115457.	1.4	0
497	Facts, Patterns, and Principles in Drug Discovery: Appraising the Rule of 5 with Measured Physicochemical Data. Journal of Medicinal Chemistry, 2020, 63, 10091-10108.	2.9	62

#	Article	IF	Citations
498	Rushed Innovation: Evidence from Drug Licensing. Management Science, 2021, 67, 257-278.	2.4	13
499	Cucurbitacin mediated regulation of deregulated oncogenic signaling cascades and non-coding RNAs in different cancers: Spotlight on JAK/STAT, Wnt/Î²-catenin, mTOR, TRAIL-mediated pathways. Seminars in Cancer Biology, 2021, 73, 302-309.	4.3	21
500	Fragment Binding to Kinase Hinge: If Charge Distribution and Local pK_a Shifts Mislead Popular Bioisosterism Concepts. Angewandte Chemie - International Edition, 2021, 60, 252-258.	7.2	8
501	Three dimensional bioprinting technology: Applications in pharmaceutical and biomedical area. Colloids and Surfaces B: Biointerfaces, 2021, 197, 111396.	2.5	40
502	Fragmentâ€Bindung an die Kinaseâ€Scharnierâ€Region: Wenn Ladungsverteilung und lokale p K a â€Verschiebungen etablierte Bioisosterieâ€Konzepte fehlleiten. Angewandte Chemie, 2021, 133, 256-262.	1.6	0
503	An Oculus to Profile and Probe Target Engagement In Vivo: How T-REX Was Born and Its Evolution into G-REX. Accounts of Chemical Research, 2021, 54, 618-631.	7.6	20
504	Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of Structurally Diverse Clinical Compounds. Drug Metabolism and Disposition, 2021, 49, 169-178.	1.7	20
505	Pumpless, unidirectional microphysiological system for testing metabolismâ€dependent chemotherapeutic toxicity. Biotechnology Progress, 2021, 37, e3105.	1.3	9
506	Automation and data-driven design of polymer therapeutics. Advanced Drug Delivery Reviews, 2021, 171, 1-28.	6.6	46
507	New Associations between Drug-Induced Adverse Events in Animal Models and Humans Reveal Novel Candidate Safety Targets. Chemical Research in Toxicology, 2021, 34, 438-451.	1.7	8
508	Reviving an R&D pipeline: a step change in the Phase II success rate. Drug Discovery Today, 2021, 26, 308-314.	3.2	23
509	Predicting the Molecular Mechanism of EGFR Domain II Dimer Binding Interface by Machine Learning to Identify Potent Small Molecule Inhibitor for Treatment of Cancer. Journal of Pharmaceutical Sciences, 2021, 110, 727-737.	1.6	2
510	Organs-on-chips: into the next decade. Nature Reviews Drug Discovery, 2021, 20, 345-361.	21.5	459
511	Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets. Seminars in Cancer Biology, 2021, 68, 59-74.	4.3	64
512	Problems, challenges, and initiatives in translation. , 2021, , 9-17.		1
513	Orphan drugs: why is translation so successful?. , 2021, , 351-355.		0
514	High-Throughput Detection of Ligand-Protein Binding Using a SplitLuc Cellular Thermal Shift Assay. Methods in Molecular Biology, 2021, 2365, 21-41.	0.4	7
515	Multi-Target Drugs as Master Keys to Complex Diseases: Inverse Docking Strategies and Opportunities. , 2021, , 295-311.		0

#	ARTICLE	IF	CITATIONS
516	Drugmonizome and Drugmonizome-ML: integration and abstraction of small molecule attributes for drug enrichment analysis and machine learning. Database: the Journal of Biological Databases and Curation, 2021, 2021, .	1.4	19
517	Approaches for the integration of big data in translational medicine: single‐cell and computational methods. Annals of the New York Academy of Sciences, 2021, 1493, 3-28.	1.8	8
518	Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century. Mini-Reviews in Medicinal Chemistry, 2021, 21, 3-9.	1.1	6
519	The right tools for the job: the central role for next generation chemical probes and chemistry-based target deconvolution methods in phenotypic drug discovery. RSC Medicinal Chemistry, 2021, 12, 646-665.	1.7	6
520	hiPSC-Derived Neurons Provide a Robust and Physiologically Relevant In Vitro Platform to Test Botulinum Neurotoxins. Frontiers in Pharmacology, 2020, 11, 617867.	1.6	11
521	3D cell culture for pharmaceutical application. , 2021, , 261-282.		0
522	The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS). BMC Medicine, 2021, 19, 13.	2.3	52
523	Cryopreservable arrays of paper-based 3D tumor models for high throughput drug screening. Lab on A Chip, 2021, 21, 844-854.	3.1	13
524	Optimisation of Passive Permeability for Oral Absorption. RSC Drug Discovery Series, 2021, , 36-61.	0.2	0
525	<i>In vivo</i> protein corona on nanoparticles: does the control of all material parameters orient the biological behavior?. Nanoscale Advances, 2021, 3, 1209-1229.	2.2	52
526	State of the evidence: a survey of global disparities in clinical trials. BMJ Global Health, 2021, 6, e004145.	2.0	8
527	Impact of structural biologists and the Protein Data Bank on small-molecule drug discovery and development. Journal of Biological Chemistry, 2021, 296, 100559.	1.6	23
528	Skipped Fluorination Motifs: Synthesis of Building Blocks and Comparison of Lipophilicity Trends with Vicinal and Isolated Fluorination Motifs. Journal of Organic Chemistry, 2021, 86, 1882-1900.	1.7	12
529	Virtual Libraries for Docking Methods: Guidelines for the Selection and the Preparation. , 2021, , 99-117.		1
530	Antioxidant Drug Design: Historical and Recent Developments. Journal of Pharmaceutical Research International, 0, , 36-56.	1.0	7
531	The potential of complex in vitro models in pharmaceutical toxicology. , 2021, , 115-127.		0
532	Multi-Compartment Lymph-Node-on-a-Chip Enables Measurement of Immune Cell Motility in Response to Drugs. Bioengineering, 2021, 8, 19.	1.6	9
533	Pharmacokinetic characterization of drugs and new product development. , 2021, , 195-277.		2

#	Article	IF	Citations
534	Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient. , 2021, , 1-6.		0
535	GC-MS analysis and in silico assessment of constituents of Psidium guajava leaf extract against DNA gyrase of Salmonella enterica serovar Typhi. Informatics in Medicine Unlocked, 2021, 26, 100722.	1.9	7
536	Computational Drug Target Tractability Analysis. , 2021, , 145-153.		1
537	A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria. Toxicology Research, 2021, 10, 203-213.	0.9	8
538	Comparison of Acute Effects of Neurotoxic Compounds on Network Activity in Human and Rodent Neural Cultures. Toxicological Sciences, 2021, 180, 295-312.	1.4	12
539	Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2. International Journal of Molecular Sciences, 2021, 22, 2065.	1.8	3
540	Molecular docking and ADMET studies of Allium cepa, Azadirachta indica and Xylopia aethiopica isolates as potential anti-viral drugs for Covid-19. VirusDisease, 2021, 32, 85-97.	1.0	25
541	The emergence of imaging mass spectrometry in drug discovery and development: Making a difference by driving decision making. Journal of Mass Spectrometry, 2021, 56, e4717.	0.7	12
542	Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting. ACS Chemical Neuroscience, 2021, 12, 1007-1017.	1.7	6
543	The influence of calculated physicochemical properties of compounds on their ADMET profiles. Bioorganic and Medicinal Chemistry Letters, 2021, 36, 127825.	1.0	2
544	Natural Products, the Fourth Industrial Revolution, and the Quintuple Helix. Natural Product Communications, 2021, 16, 1934578X2110030.	0.2	1
545	A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. 3 Biotech, 2021, 11, 198.	1.1	15
546	Precision Medicine and cardiac channelopathies: when dreams meet reality. European Heart Journal, 2021, 42, 1661-1675.	1.0	34
547	A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate <i>Pseudomonas aeruginosa</i> Biofilms. Advanced Science, 2021, 8, e2004369.	5.6	34
548	Particle Forming Amorphous Solid Dispersions: A Mechanistic Randomized Pharmacokinetic Study in Humans. Pharmaceutics, 2021, 13, 401.	2.0	0
549	Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review. Scientific Reports, 2021, 11, 6403.	1.6	27
550	In Silico Prediction of Fraction Unbound in Human Plasma from Chemical Fingerprint Using Automated Machine Learning. ACS Omega, 2021, 6, 6791-6797.	1.6	14
551	Human iPSC modeling of heart disease for drug development. Cell Chemical Biology, 2021, 28, 271-282.	2.5	21

#	Article	IF	Citations
552	One-pot parallel synthesis of 1,3,5-trisubstituted 1,2,4-triazoles. Molecular Diversity, 2022, 26, 993-1004.	2.1	4
554	ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Research, 2021, 49, W5-W14.	6.5	915
556	An automated approach to identify scientific publications reporting pharmacokinetic parameters. Wellcome Open Research, 2021, 6, 88.	0.9	7
557	Azatricyclic Inverse Agonists of RORÎ³t That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis. ACS Medicinal Chemistry Letters, 2021, 12, 827-835.	1.3	3
559	Few-Shot Graph Learning for Molecular Property Prediction. , 2021, , .		41
560	Comparison Accuracy of Multi-Layer Perceptron and DNN in QSAR Classification for Acetylcholinesterase Inhibitors. , 2021, , .		2
561	Innovation in breakthrough drugs and vaccines: Development risk, patient impact, and value. Drug Discovery Today, 2021, 26, 2232-2237.	3.2	2
562	The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development. Pharmaceutics, 2021, 13, 704.	2.0	11
563	Evidence for Specific Receptorâ€Mediated Toxicity of Pharmaceuticals in Aquatic Organisms Derived from Acute and Chronic Standard Endpoints. Environmental Toxicology and Chemistry, 2021, , .	2.2	3
564	Target-Based Evaluation of â€œDrug-Likeâ€•Properties and Ligand Efficiencies. Journal of Medicinal Chemistry, 2021, 64, 7210-7230.	2.9	46
565	Introduction to the EQIPD quality system. ELife, 2021, 10, .	2.8	42
566	Crystallization Risk Assessment of Amorphous Solid Dispersions by Physical Shelf-Life Modeling: A Practical Approach. Molecular Pharmaceutics, 2021, 18, 2428-2437.	2.3	9
567	FRET-Based Probe for High-Throughput DNA Intercalator Drug Discovery and In Vivo Imaging. ACS Sensors, 2021, 6, 2233-2240.	4.0	3
568	Revisiting stacking interactions in tetrathiafulvalene and selected derivatives using tight-binding quantum chemical calculations and local coupled-cluster method. Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 2021, 77, 311-320.	0.5	6
569	Prediction of hERG inhibition of drug discovery compounds using biomimetic HPLC measurements. ADMET and DMPK, 2021, 9, 191-207.	1.1	4
570	Drug-Rich Phases Induced by Amorphous Solid Dispersion: Arbitrary or Intentional Goal in Oral Drug Delivery?. Pharmaceutics, 2021, 13, 889.	2.0	17
571	Driving success in personalized medicine through AI-enabled computational modeling. Drug Discovery Today, 2021, 26, 1459-1465.	3.2	9
572	Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation. Drug Metabolism and Disposition, 2021, 49, 683-693.	1.7	30

#	ARTICLE	IF	CITATIONS
573	Pharmaceutical innovation and its crisis: drug markets, screening, and the dialectics of value. BioSocieties, 2021, 16, 411-432.	0.8	3
574	Large scale meta-analysis of preclinical toxicity data for target characterisation and hypotheses generation. PLoS ONE, 2021, 16, e0252533.	1.1	3
575	Modeling adaptive drug resistance of colorectal cancer and therapeutic interventions with tumor spheroids. Experimental Biology and Medicine, 2021, 246, 2372-2380.	1.1	3
576	Lipid membrane-based therapeutics and diagnostics. Archives of Biochemistry and Biophysics, 2021, 704, 108858.	1.4	4
578	Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity. Expert Opinion on Drug Discovery, 2021, 16, 1365-1390.	2.5	7
579	Validating ADME QSAR Models Using Marketed Drugs. SLAS Discovery, 2021, 26, 1326-1336.	1.4	16
580	Analytical and Omics-Based Advances in the Study of Drug-Induced Liver Injury. Toxicological Sciences, 2021, 183, 1-13.	1.4	16
581	Human‎induced pluripotent stem cell‎derived cardiomyocytes: Cardiovascular properties and metabolism and pharmacokinetics of deuterated mexiletine analogs. Pharmacology Research and Perspectives, 2021, 9, e00828.	1.1	3
582	Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma. Journal of Experimental Medicine, 2021, 218, .	4.2	31
583	In Silico Prediction, Molecular Docking and Dynamics Studies of Steroidal Alkaloids of Holarrhena pubescens Wall. ex G. Don to Guanylyl Cyclase C: Implications in Designing of Novel Antidiarrheal Therapeutic Strategies. Molecules, 2021, 26, 4147.	1.7	6
584	Proteomics in the pharmaceutical and biotechnology industry: a look to the next decade. Expert Review of Proteomics, 2021, 18, 503-526.	1.3	21
586	Highly Multiplexed Kinase Profiling in Spleen with Targeted Mass Spectrometry Reveals Kinome Plasticity across Species. Journal of Proteome Research, 2021, 20, 4272-4283.	1.8	4
587	Sensitive Measurement of Drug-Target Engagement by a Cellular Thermal Shift Assay with Multiplex Proximity Extension Readout. Analytical Chemistry, 2021, 93, 10999-11009.	3.2	9
588	Emerging Opportunities in Human Pluripotent Stem-Cells Based Assays to Explore the Diversity of Botulinum Neurotoxins as Future Therapeutics. International Journal of Molecular Sciences, 2021, 22, 7524.	1.8	2
589	Genetic Prioritization, Therapeutic Repositioning and Cross-Disease Comparisons Reveal Inflammatory Targets Tractable for Kidney Stone Disease. Frontiers in Immunology, 2021, 12, 687291.	2.2	6
591	Organs-on-chip models for cardiovascular drug development. Cardiovascular Research, 2021, 117, e164-e165.	1.8	5
592	Opinion on Maintaining In-House GLP Status for Toxicologic Pathology in Pharmaceutical and (Agro)Chemical Development. Toxicologic Pathology, 2021, , 019262332110422.	0.9	0
593	TrendyGenes, a computational pipeline for the detection of literature trends in academia and drug discovery. Scientific Reports, 2021, 11, 15747.	1.6	4

#	ARTICLE	IF	CITATIONS
594	Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development. Cells Tissues Organs, 2022, 211, 269-281.	1.3	16
595	A Chemoproteomics Approach to Determine the Mechanism of Testicular Toxicity for the Bruton's Tyrosine Kinase Inhibitor CC-292. Journal of Pharmacology and Experimental Therapeutics, 2021, 379, 166-174.	1.3	0
596	SimilarityLab: Molecular Similarity for SAR Exploration and Target Prediction on the Web. Processes, 2021, 9, 1520.	1.3	1
597	Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin. AAPS Journal, 2021, 23, 104.	2.2	8
598	Targeting Reactive Oxygen Species Capacity of Tumor Cells with Repurposed Drug as an Anticancer Therapy. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-17.	1.9	13
599	A two-stage drop-the-losers design for time-to-event outcome using a historical control arm. Pharmaceutical Statistics, 2022, 21, 268-288.	0.7	0
600	One-Step Synthesis of Photoaffinity Probes for Live-Cell MS-Based Proteomics. Chemistry - A European Journal, 2021, 27, 17880-17888.	1.7	7
602	Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells. Oncotarget, 2021, 12, 2022-2038.	0.8	3
603	Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine. Drug Discovery Today, 2022, 27, 215-222.	3.2	35
604	Logistic regression and random forest unveil key molecular descriptors of druglikeness. Chem-Bio Informatics Journal, 2021, 21, 39-58.	0.1	1
605	Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design. Journal of Medicinal Chemistry, 2021, 64, 14046-14128.	2.9	171
606	Drug Target Identification in Tissues by Thermal Proteome Profiling. Annual Review of Pharmacology and Toxicology, 2022, 62, 465-482.	4.2	31
607	Designing small molecules for therapeutic success: A contemporary perspective. Drug Discovery Today, 2022, 27, 538-546.	3.2	8
608	The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes. Molecules, 2021, 26, 5629.	1.7	14
609	Characterizing interdisciplinarity in drug research: A translational science perspective. Journal of Informetrics, 2021, 15, 101216.	1.4	3
610	Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing. Computers in Biology and Medicine, 2021, 138, 104856.	3.9	12
611	Strategies for the design of nanoparticles: starting with long-circulating nanoparticles, from lab to clinic. Biomaterials Science, 2021, 9, 3621-3637.	2.6	12
612	Early preclinical screening using zebrafish (Danio rerio) reveals the safety of the candidate anti-inflammatory therapeutic agent TnP. Toxicology Reports, 2021, 8, 13-22.	1.6	11

#	ARTICLE	IF	CITATIONS
613	Collaborative virtual screening to elaborate an imidazo[1,2-*a*]pyridine hit series for visceral leishmaniasis. RSC Medicinal Chemistry, 2021, 12, 384-393.	1.7	17
614	Key Aspects for Achieving Hits by Virtual Screening Studies. Engineering Materials, 2021, , 455-487.	0.3	3
615	A toolkit of methods of development-focused health technology assessment. International Journal of Technology Assessment in Health Care, 2021, 37, .	0.2	5
616	Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 195-201.	1.3	3
617	Chemogenomics for drug discovery: clinical molecules from open access chemical probes. RSC Chemical Biology, 2021, 2, 759-795.	2.0	11
618	Stem Cells for Next Level Toxicity Testing in the 21st Century. Small, 2021, 17, e2006252.	5.2	41
619	Current and Future Challenges in Modern Drug Discovery. Methods in Molecular Biology, 2020, 2114, 1-17.	0.4	10
620	QM Calculations in ADMET Prediction. Methods in Molecular Biology, 2020, 2114, 285-305.	0.4	7
621	Target Safety Assessment: Strategies and Resources. Methods in Molecular Biology, 2017, 1641, 213-228.	0.4	9
622	Phenotypic Screening of iPSC-Derived Cardiomyocytes for Cardiotoxicity Testing and Therapeutic Target Discovery. , 2019, , 19-34.		1
623	Organs-on-a-Chip. Advances in Experimental Medicine and Biology, 2020, 1230, 27-42.	0.8	21
624	Engineering Patient-on-a-Chip Models for Personalized Cancer Medicine. Advances in Experimental Medicine and Biology, 2020, 1230, 43-64.	0.8	12
625	Molecular Aspects of Histamine Receptors. Receptors, 2016, , 1-49.	0.2	5
626	Machine learning strategies for identifying repurposed drugs for cancer therapy. , 2020, , 55-79.		1
627	A perspective on the discovery of selected compounds with anthelmintic activity against the barber's pole wormâ€"Where to from here?. Advances in Parasitology, 2020, 108, 1-45.	1.4	17
628	Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations. Bioorganic and Medicinal Chemistry, 2020, 28, 115715.	1.4	5
629	Current status and future directions of high-throughput ADME screening in drug discovery. Journal of Pharmaceutical Analysis, 2020, 10, 201-208.	2.4	51
631	Transcriptomic Analysis of the Activity and Mechanism of Action of a Ruthenium(II)-Based Antimicrobial That Induces Minimal Evolution of Pathogen Resistance. ACS Pharmacology and Translational Science, 2021, 4, 168-178.	2.5	11

#	Article	IF	Citations
632	Novel p38Î± MAP kinase inhibitors identified from yoctoReactor DNA-encoded small molecule library. MedChemComm, 2016, 7, 1332-1339.	3.5	68
633	Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1â€"JNK axis. Journal of Biological Chemistry, 2020, 295, 18328-18342.	1.6	17
642	Using regulatory genomics data to interpret the function of disease variants and prioritise genes from expression studies. F1000Research, 2018, 7, 121.	0.8	4
643	Inhibitory effects and mechanism of dihydroberberine on hERG channels expressed in HEK293 cells. PLoS ONE, 2017, 12, e0181823.	1.1	11
644	Biology-inspired microphysiological systems to advance medicines for patient benefit and animal welfare. ALTEX: Alternatives To Animal Experimentation, 2020, 37, 365-394.	0.9	123
645	Integral estimation of xenobioticsâ€™ toxicity with regard to their metabolism in human organism. Pure and Applied Chemistry, 2017, 89, 1449-1458.	0.9	8
646	4 Ds in health researchâ€"working together toward rapid precision medicine. EMBO Molecular Medicine, 2019, 11, e10917.	3.3	7
647	A Case Report: Building communities with training and resources for Open Science trainers. LIBER Quarterly, 2018, 29, 1.	0.6	1
648	Organotypic three-dimensional cancer cell cultures mirror drug responses *in vivo*: lessons learned from the inhibition of EGFR signaling. Oncotarget, 2017, 8, 107423-107440.	0.8	36
649	Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. Oncotarget, 2018, 9, 18540-18547.	0.8	15
650	Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences. Current Pharmaceutical Biotechnology, 2020, 21, 787-806.	0.9	12
651	Drug Repositioning for COVID-19. Colombia Medica, 2020, 51, e4279.	0.7	5
652	Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds. International Journal of Molecular Sciences, 2020, 21, 3626.	1.8	131
653	Multi-Compartment 3D-Cultured Organ-on-a-Chip: Towards a Biomimetic Lymph Node for Drug Development. Pharmaceutics, 2020, 12, 464.	2.0	42
654	Generative network complex (GNC) for drug discovery. Communications in Information and Systems, 2019, 19, 241-277.	0.3	14
655	Harmonizing solubility measurement to lower inter-laboratory variance â€" progress of consortium of biopharmaceutical tools (CoBiTo) in Japan. ADMET and DMPK, 2019, 7, 183-195.	1.1	10
656	A quantitative systems pharmacology approach to support mRNA vaccine development and optimization. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1448-1451.	1.3	8
657	Converting extracellular vesicles into nanomedicine: loading and unloading of cargo. Materials Today Nano, 2021, 16, 100148.	2.3	19

#	ARTICLE	IF	CITATIONS
659	Evaluation of FOXO1 Target Engagement Using a Single-Cell Microfluidic Platform. Analytical Chemistry, 2021, 93, 14659-14666.	3.2	5
660	Modelling Human Physiology on-Chip: Historical Perspectives and Future Directions. Micromachines, 2021, 12, 1250.	1.4	9
661	Mining drugâ€"target and drugâ€"adverse drug reaction databases to identify targetâ€"adverse drug reaction relationships. Database: the Journal of Biological Databases and Curation, 2021, 2021, .	1.4	3
662	Role of peer support in a hepatitis C elimination programme. Journal of Viral Hepatitis, 2022, 29, 43-51.	1.0	8
663	Application of Humanised and Other Transgenic Models to Predict Human Responses to Drugs. RSC Drug Discovery Series, 2015, , 152-176.	0.2	0
666	Chapter 8. Human Embryonic Stem Cells as Biological Models to Examine the Impact of Xenobiotics on the Genome and Epigenome. Issues in Toxicology, 2016, , 236-246.	0.2	0
667	Combinatorial Therapeutic Discovery Using Perturbational Gene-Expression Signatures. SSRN Electronic Journal, 0, , .	0.4	0
668	Using regulatory genomics data to interpret the function of disease variants and prioritise genes from expression studies. F1000Research, 2018, 7, 121.	0.8	3
670	(Clinical) Trial and Error in Diabetic Nephropathy. , 2019, , 415-431.		0
671	Drug Screening Platforms and RPPA. Advances in Experimental Medicine and Biology, 2019, 1188, 203-226.	0.8	4
672	Drug Discovery and Development. , 2019, , 87-136.		0
673	Rushed Innovation: Reactive Licensing in the Pharmaceutical Industry. SSRN Electronic Journal, 0, , .	0.4	0
676	Advances in In-Silico based Predictive In-Vivo Profiling of Novel Potent Î²-Glucuronidase Inhibitors. Current Cancer Drug Targets, 2019, 19, 906-918.	0.8	2
679	SialoPen peptides are new cationic foldamers with remarkable cell permeability. Heliyon, 2020, 6, e05780.	1.4	3
680	Discovering Gene-Disease Associations with Biomedical Word Embeddings. , 2020, , .		2
681	Phenotypic Drug Discovery: History, Evolution, Future. RSC Drug Discovery Series, 2020, , 1-19.	0.2	4
686	Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints. Methods in Molecular Biology, 2022, 2390, 61-101.	0.4	3
687	Opportunities and Considerations in the Application of Artificial Intelligence to Pharmacokinetic Prediction. Methods in Molecular Biology, 2022, 2390, 461-482.	0.4	4

#	Article	IF	Citations
689	Small Molecule Regulation of Stem Cells that Generate Bone, Chondrocyte, and Cardiac Cells. Current Topics in Medicinal Chemistry, 2020, 20, 2344-2361.	1.0	0
690	Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biology and Medicine, 2015, 12, 316-27.	1.4	5
692	The role of DMPK science in improving pharmaceutical research and development efficiency. Drug Discovery Today, 2022, 27, 705-729.	3.2	7
693	Cardiovascular Drugs: an Insight of In Silico Drug Design Tools. Journal of Pharmaceutical Innovation, 2022, 17, 1484-1509.	1.1	2
694	Maxsmi: Maximizing molecular property prediction performance with confidence estimation using SMILES augmentation and deep learning. Artificial Intelligence in the Life Sciences, 2021, 1, 100014.	1.6	6
695	How does basic research improve innovation performance in the world's major pharmaceutical firms?. Industry and Innovation, 2022, 29, 396-424.	1.7	11
696	Measuring the rapid kinetics of receptor-ligand interactions in live cells using NanoBRET. Methods in Cell Biology, 2021, 166, 1-14.	0.5	1
697	Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. Journal of Controlled Release, 2022, 341, 676-701.	4.8	16
698	Transcription Factor Activation Profiles (TFAP) identify compounds promoting differentiation of Acute Myeloid Leukemia cell lines. Cell Death Discovery, 2022, 8, 16.	2.0	0
699	Organ-on-a-chip technologies to study neuromuscular disorders: possibilities, limitations, and future hopes. Medizinische Genetik, 2021, 33, 261-267.	0.1	0
700	Differential toxicity to murine small and large intestinal epithelium induced by oncology drugs. Communications Biology, 2022, 5, 99.	2.0	2
701	Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors. Nature Communications, 2022, 13, 569.	5.8	17
702	Advanced Analytical Tools for the Estimation of Gut Permeability of Compounds of Pharmaceutical Interest. Applied Sciences (Switzerland), 2022, 12, 1326.	1.3	2
703	Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0199121.	1.4	103
704	Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery. Journal of Medicinal Chemistry, 2022, 65, 1685-1694.	2.9	7
705	The Use of Bioactive Compounds in Hyperglycemia- and Amyloid Fibrils-Induced Toxicity in Type 2 Diabetes and Alzheimer's Disease. Pharmaceutics, 2022, 14, 235.	2.0	15
706	Bugs on Drugs: A Drosophila melanogaster Gut Model to Study In Vivo Antibiotic Tolerance of E. coli. Microorganisms, 2022, 10, 119.	1.6	5
707	An Overview of Organs-on-Chips Based on Deep Learning. Research, 2022, 2022, 9869518.	2.8	31

#	Article	IF	Citations
708	Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Developmentâ€"Current State-of-the-Art and Future Perspectives. Pharmacological Reviews, 2022, 74, 141-206.	7.1	23
709	Introduction and Historical Overview of Drug Repurposing Opportunities. RSC Drug Discovery Series, 2022, , 1-13.	0.2	4
710	HobPre: accurate prediction of human oral bioavailability for small molecules. Journal of Cheminformatics, 2022, 14, 1.	2.8	32
711	Toxicity testing of natural products using the zebrafish model system. , 2022, , 531-554.		0
712	OUP accepted manuscript. Briefings in Bioinformatics, 2022, , .	3.2	8
713	Dissecting the Mechanism of Action of Spiperoneâ€"A Candidate for Drug Repurposing for Colorectal Cancer. Cancers, 2022, 14, 776.	1.7	3
714	Antitrypanosomal properties of Anogeissus leiocarpa extracts and their inhibitory effect on trypanosome alternative oxidase. Phytomedicine Plus, 2022, 2, 100223.	0.9	3
715	Improving Small-Molecule Force Field Parameters in Ligand Binding Studies. Frontiers in Molecular Biosciences, 2021, 8, 760283.	1.6	8
717	Increasing the Value of Data Within a Large Pharmaceutical Company Through In Silico Models. Methods in Molecular Biology, 2022, 2425, 637-674.	0.4	2
718	From random to predictive: a context-specific interaction framework improves selection of drug proteinâ€"protein interactions for unknown drug pathways. Integrative Biology (United Kingdom), 2022, 14, 13-24.	0.6	5
719	Pharmacokinetic Tools and Applications. Methods in Molecular Biology, 2022, 2425, 57-83.	0.4	3
720	Knowledge-based BERT: a method to extract molecular features like computational chemists. Briefings in Bioinformatics, 2022, 23, .	3.2	24
721	In Silico Tools and Software to Predict ADMET of New Drug Candidates. Methods in Molecular Biology, 2022, 2425, 85-115.	0.4	15
722	Drug Designâ€"Past, Present, Future. Molecules, 2022, 27, 1496.	1.7	24
723	Recycled Translation: Repurposing Drugs for Stroke. Translational Stroke Research, 2022, 13, 866-880.	2.3	5
724	Dissecting Drug-Induced Cytotoxicity and Metabolic Dysfunction in Conditionally Immortalized Human Proximal Tubule Cells. Frontiers in Toxicology, 2022, 4, 842396.	1.6	3
725	Induction of Liver Size Reduction in Zebrafish Larvae by the Emerging Synthetic Cannabinoid 4F-MDMB-BINACA and Its Impact on Drug Metabolism. Molecules, 2022, 27, 1290.	1.7	5
726	NeuralDock: Rapid and Conformation-Agnostic Docking of Small Molecules. Frontiers in Molecular Biosciences, 2022, 9, 867241.	1.6	3

#	ARTICLE	IF	CITATIONS
727	Dopamine D3 receptor ligands: a patent review (2014–2020). Expert Opinion on Therapeutic Patents, 2022, 32, 605-627.	2.4	1
728	Formation of Ciprofloxacin–Isonicotinic Acid Cocrystal Using Mechanochemical Synthesis Routes–An Investigation into Critical Process Parameters. Pharmaceutics, 2022, 14, 634.	2.0	5
729	The emerging role of mass spectrometry-based proteomics in drug discovery. Nature Reviews Drug Discovery, 2022, 21, 637-654.	21.5	110
730	Strategic, feasibility, economic, and cultural aspects of phase 0 approaches. Clinical and Translational Science, 2022, 15, 1355-1379.	1.5	6
731	The Physical Stability of Felodipine and Its Recrystallization from an Amorphous Solid Dispersion Studied by NMR Relaxometry. AAPS PharmSciTech, 2022, 23, 93.	1.5	2
732	Optimization of a Pyrimidinone Series for Selective Inhibition of Ca^{2+}/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain. Journal of Medicinal Chemistry, 2022, 65, 4667-4686.	2.9	3
733	Novel tryptanthrin hybrids bearing aminothiazoles as potential EGFR inhibitors: Design, synthesis, biological screening, molecular docking studies, and ADME/T predictions. Journal of Heterocyclic Chemistry, 2022, 59, 1533-1550.	1.4	5
734	Why medicines work. , 2022, 238, 108175.		1
735	Pharmacokinetics and drug-likeness of antidiabetic flavonoids: Molecular docking and DFT study. PLoS ONE, 2021, 16, e0260853.	1.1	50
736	Improving the assessment of the probability of success in late stage drug development. Pharmaceutical Statistics, 2022, 21, 439-459.	0.7	7
737	Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays. Viruses, 2022, 14, 69.	1.5	5
738	AI-based protein structure databases have the potential to accelerate rare diseases research: AlphaFoldDB and the case of IAHSP/Alsin. Drug Discovery Today, 2022, 27, 1652-1660.	3.2	14
739	Molecular docking and pharmacokinetics studies of *Curcuma longa* (Curcumin) potency against Ebola virus. Analele UniversitÄƒÈ›ii Ovidius ConstanÈ›a: Seria Chimie, 2022, 33, 22-35.	0.2	1
740	The *N,N,O*-Trisubstituted Hydroxylamine Isostere and Its Influence on Lipophilicity and Related Parameters. ACS Medicinal Chemistry Letters, 2022, 13, 799-806.	1.3	4
741	Combinations of Drug Candidate Properties Affecting Development Success and Discontinuation for 5 Diseases: Lymphoma, Non–Small Cell Lung Cancer, Arthritis, Depression, and Alzheimer Disease. Journal of Clinical Pharmacology, 2022, 62, 1247-1256.	1.0	0
752	PiER: web-based facilities tailored for genetic target prioritisation harnessing human disease genetics, functional genomics and protein interactions. Nucleic Acids Research, 2022, 50, W583-W592.	6.5	5
753	Supersaturation-Based Drug Delivery Systems: Strategy for Bioavailability Enhancement of Poorly Water-Soluble Drugs. Molecules, 2022, 27, 2969.	1.7	8
754	Non-destructive monitoring of 3D cell cultures: new technologies and applications. PeerJ, 2022, 10, e13338.	0.9	4

#	ARTICLE	IF	CITATIONS
755	Potential and Therapeutic Roles of Diosmin in Human Diseases. Biomedicines, 2022, 10, 1076.	1.4	39
756	Spatial analysis of drug absorption, distribution, metabolism, and toxicology using mass spectrometry imaging. Biochemical Pharmacology, 2022, 201, 115080.	2.0	17
757	Off-targetP ML: an open source machine learning framework for off-target panel safety assessment of small molecules. Journal of Cheminformatics, 2022, 14, 27.	2.8	5
758	Bench to bedside: The ambitious goal of transducing medicinal chemistry from the lab to the clinic. Bioorganic and Medicinal Chemistry Letters, 2022, 69, 128787.	1.0	1
759	Zebrafish for modeling stroke and their applicability for drug discovery and development. Expert Opinion on Drug Discovery, 2022, 17, 559-568.	2.5	3
760	Monitoring haemodynamic changes in rodent models to better inform safety pharmacology: Novel insights from <i>in vivo</i> studies and waveform analysis. JRSM Cardiovascular Disease, 2022, 11, 204800402210928.	0.4	1
761	IDL-PPBopt: A Strategy for Prediction and Optimization of Human Plasma Protein Binding of Compounds via an Interpretable Deep Learning Method. Journal of Chemical Information and Modeling, 2022, 62, 2788-2799.	2.5	9
764	Inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancers. International Journal of Transgender Health, 2022, 15, 568-601.	1.1	2
766	Indirect action pattern: A remote and cross-organ pharmacological mechanism for drug innovation. Acta Pharmaceutica Sinica B, 2022, , .	5.7	1
767	Breakthroughs and Applications of Organ-on-a-Chip Technology. Cells, 2022, 11, 1828.	1.8	27
768	Teaching Computer-Aided Drug Design Using TeachOpenCADD. ACS Symposium Series, 0, , 135-158.	0.5	3
769	Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient. , 2022, , 217-222.		0
770	Posaconazole-amino acid cocrystals for improving solubility and oral bioavailability while maintaining antifungal activity and low In vivo toxicity. Journal of Drug Delivery Science and Technology, 2022, 74, 103491.	1.4	3
771	In Silico ADME Profiling of Salubrinal and Its Analogues. Future Pharmacology, 2022, 2, 160-197.	0.6	11
772	Recent Advances in Cancer Drug Discovery Through the Use of Phenotypic Reporter Systems, Connectivity Mapping, and Pooled CRISPR Screening. Frontiers in Pharmacology, 0, 13, .	1.6	4
773	Exploring Low-Toxicity Chemical Space with Deep Learning for Molecular Generation. Journal of Chemical Information and Modeling, 0, , .	2.5	5
774	Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models. Journal of Visualized Experiments, 2022, , .	0.2	0
776	Functionalisation of ethereal-based saturated heterocycles with concomitant aerobic Câ€"H activation and Câ€"C bond formation. Chemical Science, 2022, 13, 8626-8633.	3.7	8

#	Article	IF	Citations
777	Applications of Microfluidics and Organ-on-a-Chip in Cancer Research. Biosensors, 2022, 12, 459.	2.3	35
778	Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a modelâ€based population pharmacokinetic analysis. Cancer Chemotherapy and Pharmacology, 2022, 90, 29-44.	1.1	2
779	Industrializing AI-powered drug discovery: lessons learned from the <i>Patrimony</i> computing platform. Expert Opinion on Drug Discovery, 2022, 17, 815-824.	2.5	5
780	Do AutoML-Based QSAR Models Fulfill OECD Principles for Regulatory Assessment? A 5-HT1A Receptor Case. Pharmaceutics, 2022, 14, 1415.	2.0	7
782	Folic acid-mesoporous silicon nanoparticles enhance the anticancer activity of the p73-activating small molecule LEM2. International Journal of Pharmaceutics, 2022, 624, 121959.	2.6	0
784	Evaluation of rapid transepithelial electrical resistance (TEER) measurement as a metric of kidney toxicity in a high-throughput microfluidic culture system. Scientific Reports, 2022, 12, .	1.6	15
785	Improved predictability of hepatic clearance with optimal pH for acyl-glucuronidation in liver microsomes. Journal of Pharmaceutical Sciences, 2022, , .	1.6	0
786	Targeting the tamoxifen receptor within sodium channels to block osteoarthritic pain. Cell Reports, 2022, 40, 111248.	2.9	1
787	toxCSM: comprehensive prediction of small molecule toxicity profiles. Briefings in Bioinformatics, 2022, 23, .	3.2	9
788	Synthesis, Cytotoxicity, Panâ€HDAC Inhibitory Activity and Docking Study of Nâ€(2â€Aminophenyl)â€2â€arylquinolineâ€4â€and Nâ€(2â€Aminophenyl)â€2â€arylbenzo[h]quinolineâ€4â€carboxamides**. ChemistrySelect, 2022, 7, .	1.1	2
790	Systematic Analysis and Prediction of the Target Space of Bioactive Food Compounds: Filling the Chemobiological Gaps. Journal of Chemical Information and Modeling, 2022, 62, 3734-3751.	2.5	5
791	Binding energy analysis and molecular dynamic simulation studies of the designed orally active, non-toxic GABARAP modulators. Journal of Biomolecular Structure and Dynamics, 2023, 41, 6394-6412.	2.0	1
792	A History of Regulatory Animal Testing: What Can We Learn?. ATLA Alternatives To Laboratory Animals, 2022, 50, 322-329.	0.7	12
793	Causative Role of Anoxic Environment in Bacterial Regulation of Human Intestinal Function. Cellular and Molecular Bioengineering, 2022, 15, 493-504.	1.0	1
794	Combining DELs and machine learning for toxicology prediction. Drug Discovery Today, 2022, 27, 103351.	3.2	4
795	Polypharmacology in Predicting Drug Toxicity: Drug Promiscuity. , 2022, , 593-623.		0
796	Library Synthesis: Building Block Selection, Handling, and Tracking. Methods in Molecular Biology, 2022, , 1-11.	0.4	0
797	Detection of fenoldopam-induced arteritis in rats using ex vivo / in vivo MRI. Toxicology Reports, 2022, 9, 1595-1602.	1.6	1

#	ARTICLE	IF	CITATIONS
798	Nanotechnological application of peptide- and protein-based therapeutics. , 2022, , 205-238.		3
799	Rational computational approaches to predict novel drug candidates against leishmaniasis. Annual Reports in Medicinal Chemistry, 2022, , .	0.5	0
800	Elucidation of the Anticancer Potential of Selected Citrus Flavonoids Against NEDD4-1 in Breast Cancer. Revista Brasileira De Farmacognosia, 2022, 32, 796-804.	0.6	0
801	S-04-03 BrainSpheres: applications and future. Toxicology Letters, 2022, 368, S18.	0.4	0
802	Trends in small molecule drug properties: A developability molecule assessment perspective. Drug Discovery Today, 2022, 27, 103366.	3.2	18
803	LCâ€"MS/MS Phytochemical Profiling, Antioxidant Activity, and Cytotoxicity of the Ethanolic Extract of Atriplex halimus L. against Breast Cancer Cell Lines: Computational Studies and Experimental Validation. Pharmaceuticals, 2022, 15, 1156.	1.7	22
804	Monitoring drugâ€"target interactions through target engagement-mediated amplification on arrays and <i>inÂsitu</i>. Nucleic Acids Research, 2022, 50, e129-e129.	6.5	1
805	Library size in virtual screening: is it truly a numberâ€™s game?. Expert Opinion on Drug Discovery, 2022, 17, 1177-1179.	2.5	6
806	Recent advances and future prospects of functional organ-on-a-chip systems. Materials Chemistry Frontiers, 2022, 6, 3633-3661.	3.2	3
807	Nonclinical Safety Signals in PharmaPendium Improve the Predictability of Human Drug-Induced Liver Injury. Chemical Research in Toxicology, 2022, 35, 2133-2144.	1.7	1
808	Investigation of the Binding Fraction of PFAS in Human Plasma and Underlying Mechanisms Based on Machine Learning and Molecular Dynamics Simulation. Environmental Science & Technology, 2023, 57, 17762-17773.	4.6	6
809	Comparative Pharmacokinetics of a Dual Inhibitor of HIV-1, NBD-14189, in Rats and Dogs with a Proof-of-Concept Evaluation of Antiviral Potency in SCID-hu Mouse Model. Viruses, 2022, 14, 2268.	1.5	1
810	Induced Pluripotent Stem Cells, a Stepping Stone to In Vitro Human Models of Hearing Loss. Cells, 2022, 11, 3331.	1.8	3
813	1,2,3-Triazole Linked Chalcone-Morpholine Hybrids: Synthesis, <i>InÂVitro</i> Antibacterial Evaluation and <i>In Silico</i> ADMET Predictions. Polycyclic Aromatic Compounds, 2023, 43, 7093-7109.	1.4	1
814	Using human genetics to improve safety assessment of therapeutics. Nature Reviews Drug Discovery, 2023, 22, 145-162.	21.5	20
815	Training recurrent neural networks as generative neural networks for molecular structures: how does it impact drug discovery?. Expert Opinion on Drug Discovery, 2022, 17, 1071-1079.	2.5	2
816	Artificial intelligence for antiviral drug discovery in low resourced settings: A perspective. Frontiers in Drug Discovery, 0, 2, .	1.1	3
817	Strategies for 3D bioprinting of spheroids: A comprehensive review. Biomaterials, 2022, 291, 121881.	5.7	23

#	Article	IF	Citations
818	Organ-On-A-Chip Database Revealed—Achieving the Human Avatar in Silicon. Bioengineering, 2022, 9, 685.	1.6	4
820	Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities. Journal of Medicinal Chemistry, 2022, 65, 14971-14999.	2.9	8
822	Multiple-Molecule Drug Repositioning for Disrupting Progression of SARS-CoV-2 Infection by Utilizing the Systems Biology Method through Host-Pathogen-Interactive Time Profile Data and DNN-Based DTI Model with Drug Design Specifications. Stresses, 2022, 2, 405-436.	1.8	2
823	Microfluidic strategies for natural products in drug discovery: Current status and future perspectives. TrAC - Trends in Analytical Chemistry, 2022, , 116832.	5.8	1
824	Targeted Small Molecule Drug Discovery. Pediatric Oncology, 2022, , 9-24.	0.5	0
825	In-vitro dynamic dissolution/bioconversion/permeation of fosamprenavir using a novel tool with an artificial biomimetic permeation barrier and microdialysis-sampling. European Journal of Pharmaceutical Sciences, 2023, 181, 106366.	1.9	5
826	Optimizing drug discovery: An opportunity and application with reverse translational research. Health Sciences Review, 2023, 6, 100074.	0.6	0
827	Curcumin based pyrazole-thiazole hybrids as antiproliferative agents: Synthesis, pharmacokinetic, photophysical properties, and docking studies. Journal of Molecular Structure, 2023, 1275, 134633.	1.8	8
828	Few-Shot Learning for Low-Data Drug Discovery. Journal of Chemical Information and Modeling, 2023, 63, 27-42.	2.5	7
829	Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five. Drug Discovery Today, 2023, 28, 103344.	3.2	14
830	ADMETboost: a web server for accurate ADMET prediction. Journal of Molecular Modeling, 2022, 28, .	0.8	20
832	A deep learning platform to assess drug proarrhythmia risk. Cell Stem Cell, 2023, 30, 86-95.e4.	5.2	5
833	Statistical analysis of preclinical inter-species concordance of histopathological findings in the eTOX database. Regulatory Toxicology and Pharmacology, 2023, 138, 105308.	1.3	2
834	Cost-Effective Mechanical Aggregation of Cardiac Progenitors and Encapsulation in Matrigel Support Self-Organization in a Dynamic Culture Environment. International Journal of Molecular Sciences, 2022, 23, 15785.	1.8	1
835	Potential inhibitory properties of structurally modified quercetin/isohamnetin glucosides against SARS-CoV-2 Mpro; molecular docking and dynamics simulation strategies. Informatics in Medicine Unlocked, 2023, 37, 101167.	1.9	1
836	Development of Pharmacophore Models for the Important Off-Target 5-HT$_{2B}$ Receptor. Journal of Medicinal Chemistry, 2023, 66, 1509-1521.	2.9	5
837	Discovery of Tryptanthrin and Its Derivatives and Its Activities against NSCLC In Vitro via Both Apoptosis and Autophagy Pathways. International Journal of Molecular Sciences, 2023, 24, 1450.	1.8	9
838	Concept and application of the probability of pharmacological success (PoPS) as a decision tool in drug development: a position paper. Journal of Translational Medicine, 2023, 21, .	1.8	0

#	Article	IF	Citations
839	Repurposing fluoxetine to treat lymphocytic leukemia: Apoptosis induction, sigma-1 receptor upregulation, inhibition of IL-2 cytokine production, and autophagy induction. Expert Opinion on Therapeutic Targets, 0, , 1-11.	1.5	1
840	Large-scale prediction of adverse drug reactions-related proteins with network embedding. Bioinformatics, 2023, 39, .	1.8	4
841	Lipid Membrane Alterations in Tumor Spheroids Revealed by Fluorescence Lifetime Microscopy Imaging. Analytical Chemistry, 0, , .	3.2	1
842	The Future of ADME in Drug Design and Development. , 2017, , 316-342.		1
843	AI and Big Data for Drug Discovery. Integrated Science, 2022, , 121-138.	0.1	0
844	Intelligent Drug Design and Use for Cancer Treatment: The Roles of AI and Precision Oncology in Targeting Patient-Specific Splicing Profiles. , 2023, , 217-238.		0
845	Metabolism-Guided Optimization of Tryptophanol-Derived Isoindolinone p53 Activators. Pharmaceuticals, 2023, 16, 146.	1.7	3
846	Prediction of drug side effects with transductive matrix co-completion. Bioinformatics, 2023, 39, .	1.8	2
847	The Application of AI in Precision Oncology: Tailoring Diagnosis, Treatment, and the Monitoring of Disease Progression to the Patient. , 2023, , 1-25.		0
848	Structural Modifications of Polyethylenimine to Control Drug Loading and Release Characteristics of Amorphous Solid Dispersions. Molecular Pharmaceutics, 2023, 20, 1779-1787.	2.3	5
849	The Chemical Space of Terpenes: Insights from Data Science and AI. Pharmaceuticals, 2023, 16, 202.	1.7	1
851	Identifying multiscale translational safety biomarkers using a network-based systems approach. IScience, 2023, 26, 106094.	1.9	4
852	Drug Repurposing in Gastric Cancer: Current Status and Future Perspectives. , 2023, , 281-320.		0
853	Cell painting transfer increases screening hit rate. Biological Imaging, 2023, 3, .	1.0	0
854	Drug discovery: Standing on the shoulders of giants. , 2023, , 207-338.		0
855	Physicochemical properties, drug likeness, ADMET, DFT studies, and in vitro antioxidant activity of oxindole derivatives. Computational Biology and Chemistry, 2023, 104, 107861.	1.1	7
856	Few-shot learning with transformers via graph embeddings for molecular property prediction. Expert Systems With Applications, 2023, 225, 120005.	4.4	4
857	Synthetic hydrazones: In silico studies and in vitro evaluation of the antileishmania potential. Toxicology in Vitro, 2023, 88, 105560.	1.1	1

#	ARTICLE	IF	CITATIONS
858	Screening for bilayer-active and likely cytotoxic molecules reveals bilayer-mediated regulation of cell function. Journal of General Physiology, 2023, 155, .	0.9	2
859	Artificial intelligence for compound pharmacokinetics prediction. Current Opinion in Structural Biology, 2023, 79, 102546.	2.6	9
860	In silico discovery of small molecules for efficient stem cell differentiation into definitive endoderm. Stem Cell Reports, 2023, 18, 765-781.	2.3	4
861	Challenges and opportunities in the management of cardiovascular diseases. , 2022, 1, 42-46.		1
862	Old Drugs, New Indications (Review). Drug Development and Registration, 2023, 12, 182-190.	0.2	4
863	Few-shot learning via graph embeddings with convolutional networks for low-data molecular property prediction. Neural Computing and Applications, 2023, 35, 13167-13185.	3.2	2
864	Many are called, few are chosen: the role of science in drug development decisions. Journal of Technology Transfer, 0, , .	2.5	1
866	Drug discovery: Chaos can be your friend or your enemy. , 2023, , 417-511.		2
867	Backgrounderâ€"Part 1. , 2023, , 3-26.		0
868	An overview of compound properties, multiparameter optimization, and computational drug design methods for PARP-1 inhibitor drugs. European Journal of Medicinal Chemistry, 2023, 252, 115300.	2.6	5
869	Drug testing: translating a novel immunotherapeutic from bench to bedside. , 2023, , 43-51.		0
870	Chemical rules for optimization of chemical mutagenicity via matched molecular pairs analysis and machine learning methods. Journal of Cheminformatics, 2023, 15, .	2.8	3
873	Ligandâ€™s Partition to the Lipid Bilayer Should Be Accounted for When Estimating Their Affinity to Proteins. Molecules, 2023, 28, 3136.	1.7	2
874	Improved GNNs for Logâ€¯$D_{7.4}$ Prediction by Transferring Knowledge from Low-Fidelity Data. Journal of Chemical Information and Modeling, 0, , .	2.5	2
875	MTGL-ADMET: A Novel Multi-task Graph Learning Framework forÂADMET Prediction Enhanced byÂStatus-Theory andÂMaximum Flow. Lecture Notes in Computer Science, 2023, , 85-103.	1.0	0
876	Testing the limits of SMILES-based de novo molecular generation with curriculum and deep reinforcement learning. Nature Machine Intelligence, 2023, 5, 386-394.	8.3	9
877	Organ-on-a-Chip for Drug Screening: A Bright Future for Sustainability? A Critical Review. ACS Biomaterials Science and Engineering, 2023, 9, 2220-2234.	2.6	2
878	Effects of Alkoxy Chain Length and 1-Hydroxy Group on Anticolorectal Cancer Activity of 2-Bromoalkoxyanthraquinones. Medicinal Chemistry, 2023, 19, .	0.7	0

#	ARTICLE	IF	CITATIONS
879	Computational pharmacology and computational chemistry of 4-hydroxyisoleucine: Physicochemical, pharmacokinetic, and DFT-based approaches. Frontiers in Chemistry, 0, 11, .	1.8	9
880	Retrospective Analysis of Chemical Structure-Based in silico Prediction of Primary Drug Target and Off-Targets. Computational Toxicology, 2023, 26, 100273.	1.8	1
881	Discovery of Highly Potent Small Molecule Pan-Coronavirus Fusion Inhibitors. Viruses, 2023, 15, 1001.	1.5	1
882	A digitally driven manufacturing process for high resolution patterning of cell formations. Biomedical Microdevices, 2023, 25, .	1.4	0
884	Target Validation for Medicinal Chemists. , 2023, , 653-681.		1
885	Lead Optimisation: What You Should Know!. , 2023, , 720-768.		0
886	ADME Optimization in Drug Discovery. , 2023, , 298-323.		0
888	â€œPandemics-on-a-Chipâ€• Organ-on-a-Chip Models for Studying Viral Infections. , 2023, , 133-157.		0
891	Biocatalysis for Lead Discovery and Optimization. , 2022, , .		1
903	API Syntheses in Aqueous Media: Assessing the Environmental Footprint en route from Academic Discovery to Industrial Applications as â€œGreen Opportunityâ€•for Process Chemistry. Organic Process Research and Development, 2023, 27, 822-830.	1.3	5
909	Predicting unpredictable human pharmacokinetics: case studies from the trenches of drug discovery. , 2023, , 317-349.		0
910	Leveraging ADME/PK information to enable knowledge-driven decisions in drug discovery and development. , 2023, , 9-24.		0
912	Web Services for the Prediction of ADMET Parameters Relevant to the Design of Neuroprotective Drugs. Neuromethods, 2023, , 465-485.	0.2	0
913	Network Pharmacology for Drug Repositioning in Anti-Alzheimerâ€™s Drug Development. Neuromethods, 2023, , 433-463.	0.2	0
917	Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities. Cancer Chemotherapy and Pharmacology, 2023, 92, 241-251.	1.1	1
920	â€œDeep learningâ€•for healthcare: Opportunities, threats, and challenges. , 2023, , 225-244.		0
933	Computer-Aided Drug Discovery and Design: Recent Advances and Future Prospects. Methods in Molecular Biology, 2024, , 1-20.	0.4	3
940	Bioprinting in Pharmaceuticals. , 2023, , 293-325.		0

#	Article	IF	Citations
942	Editorial: Use of quantitative systems pharmacology pipelines to bridge in vitro and in vivo results in drug discovery. Frontiers in Systems Biology, 0, 3, .	0.5	0
943	In Vitro Methodologies for the Safety Assessment of Drugs. , 2023, , 79-112.		0
951	Few-shot graph and smiles learning for molecular property prediction. , 2023, , .		0
958	DRUG-INDUCED LIVER INJURY: MECHANISMS, METHODS FOR PRE-CLINICAL ASSESSMENT, AND A MEDICINAL CHEMISTâ€™S PERSPECTIVE. Medicinal Chemistry Reviews, 0, , 473-500.	0.1	0
977	Medical potentials of natural neuroprotectants derived from herbal extracts and their phytochemicals. , 2024, , 105-120.		0
978	Precision medicine: success stories and challenges from science to implementation. , 2024, , 83-113.		0
985	Emergent Applications of Organ-on-a-Chip (OOAC) Technologies With Artificial Vascular Networks in the 21st Century. Advances in Healthcare Information Systems and Administration Book Series, 2024, , 198-219.	0.2	11
987	Overview of ADME Science. , 2024, , 49-82.		0
991	Unlocking the Potential of Generative Artificial Intelligence in Drug Discovery. , 2024, , 37-63.		0
992	Dielectric Spectroscopy for Non-Invasive Sensing of Multi-Layered Organ-on-Chip Devices. , 0, , .		0